<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030003442A1-20030102-D00001.TIF SYSTEM "US20030003442A1-20030102-D00001.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00002.TIF SYSTEM "US20030003442A1-20030102-D00002.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00003.TIF SYSTEM "US20030003442A1-20030102-D00003.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00004.TIF SYSTEM "US20030003442A1-20030102-D00004.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00005.TIF SYSTEM "US20030003442A1-20030102-D00005.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00006.TIF SYSTEM "US20030003442A1-20030102-D00006.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00007.TIF SYSTEM "US20030003442A1-20030102-D00007.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00008.TIF SYSTEM "US20030003442A1-20030102-D00008.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00009.TIF SYSTEM "US20030003442A1-20030102-D00009.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00010.TIF SYSTEM "US20030003442A1-20030102-D00010.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00011.TIF SYSTEM "US20030003442A1-20030102-D00011.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00012.TIF SYSTEM "US20030003442A1-20030102-D00012.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00013.TIF SYSTEM "US20030003442A1-20030102-D00013.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00014.TIF SYSTEM "US20030003442A1-20030102-D00014.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00015.TIF SYSTEM "US20030003442A1-20030102-D00015.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00016.TIF SYSTEM "US20030003442A1-20030102-D00016.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00017.TIF SYSTEM "US20030003442A1-20030102-D00017.TIF" NDATA TIF>
<!ENTITY US20030003442A1-20030102-D00018.TIF SYSTEM "US20030003442A1-20030102-D00018.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030003442</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>09886149</doc-number>
</application-number>
<application-number-series-code>09</application-number-series-code>
<filing-date>20010622</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>P 42 33 646.5</doc-number>
</priority-application-number>
<filing-date>19921006</filing-date>
<country-code>DE</country-code>
</foreign-priority-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>P 42 35 718.7</doc-number>
</priority-application-number>
<filing-date>19921022</filing-date>
<country-code>DE</country-code>
</foreign-priority-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>P 42 44 541.8</doc-number>
</priority-application-number>
<filing-date>19921230</filing-date>
<country-code>DE</country-code>
</foreign-priority-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>P 43 18 186.4</doc-number>
</priority-application-number>
<filing-date>19930601</filing-date>
<country-code>DE</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>C12Q001/70</ipc>
</classification-ipc-primary>
<classification-ipc-secondary>
<ipc>C07H019/00</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C07H021/00</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C07H021/04</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12N005/06</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12N005/16</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>G01N033/53</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>G01N033/537</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>A61K039/21</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12N007/01</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C07K014/00</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>G01N033/561</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>G01N033/564</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>G01N033/542</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12N007/00</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C07K017/00</ipc>
</classification-ipc-secondary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>435</class>
<subclass>005000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>333000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>339100</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>536</class>
<subclass>022100</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>536</class>
<subclass>023720</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>235100</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>424</class>
<subclass>208100</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>530</class>
<subclass>350000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>436</class>
<subclass>516000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>436</class>
<subclass>531000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>007900</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>007920</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>974000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>975000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Retrovirus from the HIV group and its use</title-of-invention>
</technical-information>
<continuity-data>
<continuations>
<continuation-of>
<parent-child>
<child>
<document-id>
<doc-number>09886149</doc-number>
<kind-code>A1</kind-code>
<document-date>20010622</document-date>
</document-id>
</child>
<parent>
<document-id>
<doc-number>09109916</doc-number>
<document-date>19980702</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>PATENTED</parent-status>
</parent-child>
</continuation-of>
</continuations>
<division-of>
<parent-child>
<child>
<document-id>
<doc-number>09109916</doc-number>
<document-date>19980702</document-date>
<country-code>US</country-code>
</document-id>
</child>
<parent>
<document-id>
<doc-number>08468059</doc-number>
<document-date>19950606</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>PATENTED</parent-status>
</parent-child>
</division-of>
<division-of>
<parent-child>
<child>
<document-id>
<doc-number>08468059</doc-number>
<document-date>19950606</document-date>
<country-code>US</country-code>
</document-id>
</child>
<parent>
<document-id>
<doc-number>08132653</doc-number>
<document-date>19931005</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>ABANDONED</parent-status>
</parent-child>
</division-of>
</continuity-data>
<inventors>
<first-named-inventor>
<name>
<given-name>Lutz</given-name>
<middle-name>G.</middle-name>
<family-name>Guertler</family-name>
</name>
<residence>
<residence-non-us>
<city>Muenchen</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Josef</given-name>
<family-name>Eberle</family-name>
</name>
<residence>
<residence-non-us>
<city>Freising</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Albrecht</given-name>
<middle-name>V.</middle-name>
<family-name>Brunn</family-name>
</name>
<residence>
<residence-non-us>
<city>Augsburg</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Stefan</given-name>
<family-name>Knapp</family-name>
</name>
<residence>
<residence-non-us>
<city>Marburg-Wehrshausen</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Hans-Peter</given-name>
<family-name>Hauser</family-name>
</name>
<residence>
<residence-non-us>
<city>Marburg</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<assignee>
<organization-name>Dade Behring Marburg GmbH</organization-name>
<assignee-type>02</assignee-type>
</assignee>
<correspondence-address>
<name-1>FINNEGAN, HENDERSON, FARABOW, GARRETT &amp;</name-1>
<name-2>DUNNER LLP</name-2>
<address>
<address-1>1300 I STREET, NW</address-1>
<city>WASHINGTON</city>
<state>DC</state>
<postalcode>20005</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristic antigens which can be obtained from it and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the DNA and amino acid sequences of the virus. </paragraph>
</subdoc-abstract>
<subdoc-description>
<cross-reference-to-related-applications>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> This application is a continuation of U.S. application Ser. No. 09/109,916, filed Jul. 2, 1998, now allowed, which is a divisional application of U.S. application Ser. No. 08/468,059, filed Jun. 6, 1995, now U.S. Pat. No. 5,840,480, issued Nov. 24, 1998; which is a divisional application of U.S. application Ser. No. 08/132,653, filed Oct. 5, 1993, now abandoned; the disclosures of all of which are incorporated herein by reference.</paragraph>
</cross-reference-to-related-applications>
<summary-of-invention>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> The present invention relates to a novel retrovirus from the HIV group, as well as to variants or parts thereof which contain the essential properties of the virus. A process is described for culturing the retrovirus. The invention furthermore relates to the isolation of this retrovirus and to use of the virus, its parts or extracts for medicinal purposes, for diagnostics and in the preparation of vaccines. </paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Retroviruses which belong to the so-called HIV group lead in humans who are infected by them to disease manifestations which are summarized under the collective term immunodeficiency or AIDS (acquired immune deficiency syndrome). </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> Epidemiological studies verify that the human immunodeficiency virus (HIV) represents the etiological agent in the vast majority of AIDS (acquired immune deficiency syndrome) cases. A retrovirus which was isolated from a patient and characterized in 1983 received the designation HIV-1 (Barr&eacute;-Sinoussi, F. et al., Science 220, 868-871 &lsqb;1983&rsqb;). A variant of HIV-1 is described in WO 86/02383. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> A second group of human immunodeficiency viruses was identified in 1985 in West Africa (Clavel, F. et al., Science 233, 343-346 &lsqb;1986&rsqb;) and designated human immunodeficiency virus type 2 (HIV-2) (EP-A-0 239 425). While HIV-2 retroviruses clearly differ from HIV-1, they do exhibit affinity with simian immunodeficiency viruses (SIV-2). Like HIV-1, HIV-2 also leads to AIDS symptomatology. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> A further variant of an immunodeficiency retrovirus is described in EP-A-0 345 375 and designated there as HIV-3 retrovirus (ANT 70). </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> The isolation of a further, variant, immunodeficiency virus is also described in Lancet Vol. 340, September 1992, pp. 681-682. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> It is characteristic of human immunodeficiency viruses that they exhibit a high degree of variability, which significantly complicates the comparability of the different isolates. For example, when diverse HIV-1 isolates are compared, high degrees of variability are found in some regions of the genome while other regions are comparatively well conserved (Benn, S. et al., Science 230, 949-951 (1985&rsqb;). It was also possible to observe an appreciably greater degree of polymorphism in the case of HIV-2 (Clavel, F. et al., Nature 324, 691-695 &lsqb;1986&rsqb;). The greatest degree of genetic stability is possessed by regions in the gag and pol genes which encode proteins which are essential for structural and enzymic purposes; some regions in the env gene, and the genes (vif, vpr, tat, rev and nef) encoding regulatory proteins, exhibit a high degree of variability. In addition to this, it was possible to demonstrate that antisera against HIV-1 also crossreact with gag and po1 gene products from HIV-2 even though there was only a small degree of sequence homology. Little hybridization of significance likewise took place between these two viruses unless conditions of very low stringency were used (Clavel, F. et al., Nature 324, 691-695 &lsqb;1986&rsqb;). </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> Owing to the wide distribution of retroviruses from the HIV group and to the fact that a period of a few to many years (2-20) exists between the time of infection and the time at which unambiguous symptoms of pathological changes are recognizable, it is of great importance from the epidemiological point of view to determine infection with retroviruses of the HIV group at as early a stage as possible and, above all, in a reliable manner. This is not only of importance when diagnosing patients who exhibit signs of immunodeficiency, but also when monitoring blood donors. It has emerged that, when retroviruses of the HIV-1 or HIV-2 type, or components thereof, are used in detection systems, antibodies can either not be detected or only detected weakly in many sera even though signs of immunodeficiency are present in the patients from which the sera are derived. In certain cases, such detection is possible using the retrovirus from the HIV group according to the invention. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> This patent describes the isolation and characterization of a novel human immunodeficiency virus, designated below as MVP-5180/91 (SEQ ID NO:56), which was isolated from the peripheral lymphocytes of a female patient from the Cameroons who was 34 years old in 1991 and who exhibited signs of immunodeficiency. From the point of view of geography, this retrovirus originates from a region in Africa which is located between West Africa, where there is endemic infection with HIV-2 and HIV-1 viruses, and Eastern Central Africa, where it is almost exclusively HIV-1 which is disseminated. Consequently, the present invention relates to a novel retrovirus, designated MVP-5180/91 (SEQ ID NO:56), of the HIV group and its variants, to DNA sequences, amino acid sequences and constituent sequences derived therefrom, and to test kits containing the latter. The retrovirus MVP-5180/91 (SEQ ID NO:56) has been deposited with the European Collection of Animal Cell Cultures (ECACC) PHLS Centre for Applied Microbiology &amp; Research, Porton Down, Salisbury Wilts. SP4 0JG, United Kingdom, on Sep. 23, 1992 under ECACC Accession No. V 920 92 318 in accordance with the stipulations of the Budapest Treaty. The ECACC is located at the PHLS Centre for Applied Microbiology &amp; Research, Porton Down, Salisbury, Wilts, SP4 0JG, U.K. The deposit was made on Sep. 23, 1992, and was assigned Accession No. V 920 92 318. The date of notification of acceptance of the culture was Jan. 21, 1993. </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> As do HIV-1 and HIV-2, MVP-5180/91 (SEQ ID NO:56) according to the invention grows in the following cell lines: HUT 78, Jurkat cells, C8166 cells and MT-2 cells. The isolation and propagation of viruses is described in detail in the book &ldquo;Viral Quantitation in HIV Infection, Editor Jean-Marie Andrieu, John Libbey Eurotext, 1991&rdquo;. The procedural methods described in that publication are by reference made a subject of the disclosure of the present application. </paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> In addition to this, the virus according to the invention possesses a reverse transcriptase which is magnesium-dependent but not manganese-dependent. This represents a further property possessed in common with the HIV-1 and HIV-2 viruses. </paragraph>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> In order to provide a better understanding of the differences between the MVP-5180/91 (SEQ ID NO:56) virus according to the invention and the HIV-1 and HIV-2 retroviruses, the construction of the retroviruses which cause immunodeficiency will first of all be explained in brief. Within the virus, the RNA is located in a conical core which is assembled from protein subunits which carry the designation p 24 (p for protein). This inner core is surrounded by a protein coat, which is constructed from protein p 17 (outer core), and by a glycoprotein coat which, in addition to lipids, which originate from the host cell, contains the transmembrane protein gp 41 and the coat protein 120 (gp 120). This gp 120 can then bind to the CD-4 receptors of the host cells.</paragraph>
</summary-of-invention>
<brief-description-of-drawings>
<section>
<heading lvl="1">BRIEF DESCRIPTION OF THE DRAWINGS </heading>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 1</cross-reference> depicts the arrangement of the genome of retroviruses of the HIV type. </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 2</cross-reference> is a graph depicting the binding affinity for the monoclonal antibody p24 in relation to the content of reverse transcriptase for the retroviruses HIV-1, HIV-2, and MVP-5180/91. </paragraph>
<paragraph id="P-0016" lvl="0"><number>&lsqb;0016&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 3</cross-reference> depicts a western blot of MVP-5180/91 and HIV-1, isolated from German patients. </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 4</cross-reference> depicts the almost complete nucleic acid sequence of the retrovirus MVP-5180/91. </paragraph>
<paragraph id="P-0018" lvl="0"><number>&lsqb;0018&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 5</cross-reference> depicts the strategy for PCR amplification, cloning, and sequencing of MVP-5180/91. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 6</cross-reference> depicts a comparison of the sequence in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> and the sequence obtained using the PCR amplification techniques depicted in <cross-reference target="DRAWINGS">FIG. 5</cross-reference>. </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 7</cross-reference> depicts a comparison of the amino acid sequences of the GAG protein determined from the sequence of <cross-reference target="DRAWINGS">FIG. 4</cross-reference> with the GAG protein sequence obtained using the PCR amplification techniques depicted in <cross-reference target="DRAWINGS">FIG. 5</cross-reference>. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 8</cross-reference> depicts the immunological specificities of the V3 loop of HIV-1, HIV-2, and MVP-5180/91.</paragraph>
</section>
</brief-description-of-drawings>
<detailed-description>
<section>
<heading lvl="1">DETAILED DESCRIPTION OF THE INVENTION </heading>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> As far as is known, the RNA of HIV viruses&mdash;portrayed in a simplified manner&mdash;possesses the following gene regions: so-called long terminal repeats (LTR) at each end, together with the following gene regions: gag, pol, env and nef. The gag gene encodes, inter alia, the core proteins, p 24 and p 17, the pol gene encodes, inter alia, the reverse transcriptase, the RNAse H and the integrase, while the env gene encodes the gp 41 and gp 120 glycoproteins of the virus coat. The nef gene encodes a protein having a regulatory function. The arrangement of the genome of retroviruses of the HIV type is shown diagrammatically in <cross-reference target="DRAWINGS">FIG. 1</cross-reference>. </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> The HIV-1 and HIV-2 retroviruses can be distinguished, inter alia, by testing viral antigen using a monoclonal antibody which is commercially available from Abbott (HIVAG-l monoclonal) in the form of a test kit and is directed against (HIV-1) p 24. It is known that the content of reverse transcriptase is roughly the same in the HIV-1 and HIV-2 virus types. If, therefore, the extinction (E 490 nm.) obtained in dilutions of the disrupted viruses by means of the antigen-antibody reaction is plotted against the activity of reverse transcriptase, a series of graphs is obtained corresponding roughly to that in <cross-reference target="DRAWINGS">FIG. 2</cross-reference>. In this context, it is observed that, in the case of HIV-1, the monoclonal antibody employed has a very high binding affinity for p 24 in relation to the content of reverse transcriptase. By contrast, the monoclonal antibody employed has only a very low binding affinity for p 24 in the case of HIV-2, once again in relation to the content of reverse transcriptase. If these measurements are carried out on MVP-5180/91 (SEQ ID NO:56), the curve is then located almost precisely in the centre between the curves for HIV-1 and HIV-2, i.e. the binding affinity of the monoclonal antibody for MVP-5180/91 p 24 is reduced as compared with the case of HIV-1. <cross-reference target="DRAWINGS">FIG. 2</cross-reference> shows this relationship diagrammatically, with RT denoting reverse transcriptase, and the protein p 24, against which is directed the monoclonal antibody which is present in the test kit which can be purchased from Abbott, being employed as the antigen (Ag). </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> The so-called PCR (polymerase chain reaction) system has proved to have a multiplicity of uses in genetic manipulation, and the components which are required for implementing the process can be purchased. Using this process, it is possible to amplify DNA sequences if regions of the sequence to be amplified are known. Short, complementary DNA fragments (oligonucleotides&equals;primers) have then to be synthesized which anneal to a short region of the nucleic acid sequence to be amplified. For carrying out the test, HIV nucleic acids are introduced together with the primers into a reaction mixture which additionally contains a polymerase and nucleotide triphosphates. The polymerization (DNA synthesis) is carried out for a given time and the nucleic acid strands are then separated by heating. After cooling, the polymerization then proceeds once more. If, therefore, the retrovirus according to the invention is an HIV-1 or HIV-2 virus, it should be possible to amplify the nucleic acid using primers which are conserved within the known sequences of the HIV-1 and HIV-2 viruses. Some primers of this type have previously been described (Laur&eacute;, F. et al., Lancet ii, (1988) 538-541 for pol 3 and pol 4, and Ou C. Y. et al., Science 239 (1988) 295-297 for sk 38/39 and sk 68/69). </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> It was discovered that use of particular primer pairs having the following sequence:  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="98PT" align="left"/>
<colspec colname="2" colwidth="161PT" align="left"/>
<colspec colname="3" colwidth="-266PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row>
<entry>gaga (SEQ ID NO:1):</entry>
<entry>CTACT AGTAC CCTTC AGG</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gagb (SEQ ID NO:2):</entry>
<entry>CGGTC TACAT AGTCT CTAAA G</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>sk38 (SEQ ID NO:3):</entry>
<entry>CCACC TATCC CAGTA GGAGA A</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>sk39 (SEQ ID NO:4):</entry>
<entry>CCTTT GGTCC TTGTC TTATG TCCAG AATGC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>or</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>po13 (SEQ ID NO:5):</entry>
<entry>TGGGA AGTTC AATTA GGAAT ACCAC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>po14 (SEQ ID NO:6):</entry>
<entry>CCTAC ATAGA AATCA TCCAT GTATT G</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>po13n (SEQ ID NO:7):</entry>
<entry>TGGAT GTGGG TGATG CATA</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>po14n (SEQ ID NO:8):</entry>
<entry>AGCAC ATTGT ACTGA TATCT A</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>and</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>SK145 (SEQ ID NO:9):</entry>
<entry>AGTGG GGGGA CATCA AGCAG CC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>SK150 (SEQ ID NO:10):</entry>
<entry>TGCTA TGTCA CTTCC CCTTG GT</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>145-P (SEQ ID NO:11):</entry>
<entry>CCATG CAAAT GTTAA AAGAG AC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>150-P (SEQ ID NO:12):</entry>
<entry>GGCCT GGTGC AATAG GCCC</entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="259PT" align="left"/>
<colspec colname="2" colwidth="-266PT" align="left"/>
<tbody valign="top">
<row>
<entry>or a combination of pol 3 and pol 4 with</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="98PT" align="left"/>
<colspec colname="2" colwidth="161PT" align="left"/>
<colspec colname="3" colwidth="-266PT" align="left"/>
<tbody valign="top">
<row>
<entry>UNI-1 (SEQ ID NO:13):</entry>
<entry>GTGCT TCCAC AGGGA TGGAA</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>UNI-2 (SEQ ID NO:14):</entry>
<entry>ATCAT CCATG TATTG ATA</entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="-7PT" align="left"/>
<tbody valign="top">
<row>
<entry>(Donehower L.A. et al. (1990) J. Virol. Methods 28, 33-46)</entry>
</row>
<row>
<entry>and employing PCR with nested primers, led to weak</entry>
</row>
<row>
<entry>amplifications of the MVP-5180/91 DNA (SEQ ID NO:56).</entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> No amplification, or only weak amplification as compared with HIV-1, possibly attributable to impurities, was obtained with the following primer sequences:  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="119PT" align="left"/>
<colspec colname="2" colwidth="161PT" align="left"/>
<colspec colname="3" colwidth="-287PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row>
<entry>tat 1 (SEQ ID NO:15):</entry>
<entry>AATGG AGCCA GTAGA TCCTA</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>tat 2 (SEQ ID NO:16):</entry>
<entry>TGTCT CCGCT TCTTC CTGCC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>tat 1P (SEQ ID NO:17):</entry>
<entry>GAGCC CTGGA AGCAT CCAGG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>tat 2P (SEQ ID NO:18):</entry>
<entry>GGAGA TGCCT AAGGC TTTTG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>enva (SEQ ID NO:19):</entry>
<entry>TGTTC CTTGG GTTCT TG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>envb (SEQ ID NO:20):</entry>
<entry>GAGTT TTCCA GAGCA ACCCC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>sk68 (SEQ ID NO:21):</entry>
<entry>AGCAG CAGGA AGCAC TATGG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>sk69 (SEQ ID NO:22):</entry>
<entry>GCCCC AGACT GTGAG TTGCA ACAG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>5v3e (SEQ ID NO:23):</entry>
<entry>GCACA GTACA ATGTA CACAT GG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>3v3e (SEQ ID NO:24):</entry>
<entry>CAGTA GAAAA ATTCC CCTCC AC</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>5v3degi (SEQ ID NO:25):</entry>
<entry>TCAGG ATCCA TGGGC AGTCT AGCAG AAGAA G</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>3v3degi (SEQ ID NO:26):</entry>
<entry>ATGCT CGAGA ACTGC AGCAT CGATT CTGGG</entry>
</row>
<row>
<entry></entry>
<entry>TCCCC TCCTG AG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>3v3longdegi (SEQ ID NO:27):</entry>
<entry>CGAGA ACTGC AGCAT CGATG CTGCT</entry>
</row>
<row>
<entry></entry>
<entry>CCCAA GAACC CAAGG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>3v3longext (SEQ ID NO:28):</entry>
<entry>GGAGC TGCTT GATGC CCCAG A</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gagdi (SEQ ID NO:29):</entry>
<entry>TGATG ACAGC ATGTC AGGGA GT</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>pol e (SEQ ID NO:30):</entry>
<entry>GCTGA CATTT ATCAC AGCTG GCTAC</entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> Amplifications which were weak as compared with those for HIV-1, but nevertheless of the same intensity as those for the HIV-2 isolate (MVP-11971/87) employed, were obtained with  
<table-cwu id="TABLE-US-00003">
<number>3</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="98PT" align="left"/>
<colspec colname="2" colwidth="161PT" align="left"/>
<colspec colname="3" colwidth="-266PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row>
<entry>gag c (SEQ ID NO:31):</entry>
<entry>TATCA CCTAG AACTT TAAAT GCATG GG</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag d (SEQ ID NO:32):</entry>
<entry>AGTCC CTGAC ATGCT GTCAT CA</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>env c (SEQ ID NO:33):</entry>
<entry>GTGGA GGGGA ATTTT TCTAC TG</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>env d (SEQ ID NO:34):</entry>
<entry>CCTGC TGCTC CCAAG AACCC AAGG.</entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> The so-called Western blot (immunoblot) is a common method for detecting HIV antibodies. In this method, the viral proteins are fractionated by gel electrophoresis and then transferred to a membrane. The membranes provided with the transferred proteins are then brought into contact with sera from the patients to be investigated. If antibodies against the viral proteins are present, these antibodies will bind to the proteins. After the membranes have been washed, only antibodies which are specific for the viral proteins will remain. The antibodies are then rendered visible using antiantibodies which, as a rule, are coupled to an enzyme which catalyzes a color reaction. In this way, the bands of the viral proteins can be rendered visible. </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> The virus MVP-5180/91 (SEQ ID NO:56) according to the invention exhibits two significant and important differences from the HIV-1 and HIV-2 viruses in a Western blot. HIV-1 regularly shows a strong band, which is attributable to protein p 24, and a very weak band, which is often scarcely visible and which is attributable to protein p 23. HIV-2 exhibits a strong band, which is attributable to protein p 25, and sometimes a weak band, which is attributable to protein p 23. In contrast to this, the MVP-5180/91 (SEQ ID NO:56) virus according to the invention exhibits two bands of approximately equal strength, corresponding to proteins p 24 and p 25. </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> A further significant difference exists in the bands which are attributable to reverse transcriptase. HIV-1 shows one band (p 53) which corresponds to reverse transcriptase and one band (p 66) which corresponds to reverse transcriptase bound to RNAse H. In the case of HIV-2, the reverse transcriptase corresponds to protein p 55 and, if it is bound to RNAse H, to protein p 68. By contrast, MPV-5180/91 (SEQ ID NO:56) according to the invention exhibits one band at protein p 48, which corresponds to reverse transcriptase, and one band, at protein p 60, which corresponds to reverse transcriptase bound to RNAse H. It can be deduced from these results that the reverse transcriptase of MVP-5180/91 (SEQ ID NO:56) has a molecular weight which is roughly between 3 and 7 kilodaltons less than that of the reverse transcriptases of HIV-1 and HIV-2. The reverse transcriptase of MVP-5180 consequently has a molecular weight which is roughly between 4,500 daltons and 5,500 daltons less than that of the reverse transcriptase of HIV-1 or HIV-2. </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> It was discovered that anti-env antibodies could only be detected weakly in the sera of German patients exhibiting signs of immunodeficiency when the MVP-5180/91 (SEQ ID NO:56) virus according to the invention was used, whereas the sera reacted strongly if an HIV-1 virus was used instead of the virus according to the invention. This stronger detection reaction was located in the gp 41 protein, in particular. In the experiments, serum panels were compared which on the one hand derived from German patients and on the other from African patients showing signs of immune deficiency. </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> The abovementioned characteristics are indicative of those virus variants which correspond to MVP-5180/91 (SEQ ID NO:56) according to the invention. Therefore, the virus according to the invention, or variants thereof, can be obtained by isolating immunodeficiency viruses from heparinized donor blood derived from persons who exhibit signs of immune deficiency and who preferably originate from Africa. </paragraph>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> Since the virus possessing the abovementioned properties has been isolated, the cloning of a cDNA can be carried out in the following manner: the virus is precipitated from an appropriately large quantity of culture (about 1 l) and then taken up in phosphate-buffered sodium chloride solution. It is then pelleted through a (20% strength) sucrose cushion. The virus pellet can be suspended in 6 M guanidinium chloride in 20 mM dithiothreitol and 0.5% Nonidet P 40. CsCl is added to bring its concentration to 2 molar and the solution containing the disrupted virus is transferred to a cesium chloride cushion. The viral RNA is then pelleted by centrifugation, and subsequently dissolved, extracted with phenol and precipitated with ethanol and lithium chloride. Synthesis of the first cDNA strand is carried out on the viral RNA, or parts thereof, using an oligo(dT) primer. The synthesis can be carried out using a commercially available kit and adding reverse transcriptase. To synthesize the second strand, the RNA strand of the RNA/DNA hybrid is digested with RNase H, and the second strand is then synthesized using <highlight><italic>E. coli </italic></highlight>DNA polymerase I. Blunt ends can then be produced using T4 DNA polymerase and these ends can be joined to suitable linkers for restriction cleavage sites. Following restriction digestion with the appropriate restriction endonuclease, the cDNA fragment is isolated from an agarose gel and ligated to a vector which has previously been cut in an appropriate manner. The vector containing the cDNA insert can then be used for transforming competent <highlight><italic>E. coli </italic></highlight>cells. The colonies which are obtained are then transferred to membranes, lysed and denatured, and then finally detected by hybridization with nucleic acid labeled with digoxigenin or biotin. Once the corresponding cDNA has been prepared by genetic manipulation, it is possible to isolate the desired DNA fragments originating from the retrovirus. By incorporating these fragments into suitable expression vectors, the desired protein or protein fragment can then be expressed and employed for the diagnostic tests. </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> As an alternative to the stated method, the immunodeficiency virus can be cloned with the aid of PCR technology, it being possible to use the abovementioned primers. </paragraph>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> The similarity between different virus isolates can be expressed by the degree of homology between the nucleic acid or protein sequences. 50% homology means, for example, that 50 out of 100 nucleotides or amino acid positions in the sequences correspond to each other. The homology of proteins is determined by sequence analysis. Homologous DNA sequences can also be identified by the hybridization technique. </paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> In accordance with the invention, a part of the coat protein was initially sequenced and it was ascertained that this sequence possessed only relatively slight homology to the corresponding sequences from viruses of the HIV type. On the basis of a comparison with HIV sequences, which was carried out using data banks, it was established, in relation to the gp 41 region in particular, that the homology was at most 66% (nucleotide sequence). </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> In addition to this, the region was sequenced which encodes gp 41. This sequence is presented in Tables 1 and 3. Table 1 includes DNA SEQ ID NO:37, DNA SEQ ID NO:38, and amino acid SEQ ID NO:39. Table 3 includes DNA SEQ ID NO:44, DNA SEQ ID NO:45, and amino acid SEQ ID NO:46. </paragraph>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> The present invention therefore relates to those viruses which possess an homology of more than 66%, preferably 75% and particularly preferably 85%, to the HIV virus, MVP-5180/91 (SEQ ID NO:56), according to the invention, based on the nucleotide sequence in Table 1 (SEQ ID NO:37; SEQ ID NO:38) and/or in Table 3 (SEQ ID NO:44; SEQ ID NO:45). </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> Furthermore, the present invention relates to those viruses which possess an homology of more than 66%, preferably 75% and particularly preferably 85%, to partial sequences of the nucleotide sequence presented in Table 3 (SEQ ID NO:44; SEQ ID NO:45), which sequences are at least 50, preferably 100, nucleotides long. This corresponds to a length of the peptides of at least 16, and preferably of at least 33, amino acids. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> The sequence of the virus according to the invention differs from that of previously known viruses. The present invention therefore relates to those viruses, and corresponding DNA and amino acid sequences, which correspond to a large extent to the sequence of the virus according to the invention, the degree of deviation being established by the degree of homology. An homology of, for example, more than 85% denotes, therefore, that those sequences are included which have in at least 85 of 100 nucleotides or amino acids the same nucleotides or amino acids, respectively, while the remainder can be different. When establishing homology, the two sequences are compared in such a way that the greatest possible number of nucleotides or amino acids corresponding to each other are placed in congruence. </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> The (almost) complete sequence, given as the DNA sequence of the virus according to the invention, is reproduced in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> and included as DNA SEQ ID NO:56. In this context, the present invention relates to viruses which possess the sequence according to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56), and variants thereof which possess a high degree of homology with the sequence of <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56), as well as proteins, polypeptides and oligopeptides derived therefrom which can be used diagnostically or can be employed as vaccines. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> Using the isolated sequence as a basis, immunodominant epitopes (peptides) can be designed and synthesized. Since the nucleic acid sequence of the virus is known, the person skilled in the art can derive the amino acid sequence from this known sequence. A constituent region of the amino acid sequence is given in Table 3 (SEQ ID NO:46). The present invention also relates, therefore, to antigens, i.e. proteins, oligopeptides or polypeptides, which can be prepared with the aid of the information disclosed in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56) and Table 3 (SEQ ID NO:44; SEQ ID NO:45, and SEQ ID NO:46). These antigens, proteins, polypeptides and oligopeptides possess amino acid sequences which can either be derived from <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56) or are given in Table 3 (SEQ ID NO:46). The antigens or peptides can possess relatively short constituent sequences of an amino acid sequence which is reproduced in Table 3 (SEQ ID NO:46) or which can be derived from <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56). This amino acid sequence is at least 6, preferably at least 10 and particularly preferably at least 15, amino acids in length. These peptides can be prepared not only with the aid of recombinant technology but also using synthetic methods. A suitable preparation route is solid-phase synthesis of the Merrifield type. Further description of this technique, and of other processes known to the state of the art, can be found in the literature, e.g. M. Bodansky, et al., Peptide Synthesis, John Wiley &amp; Sons, 2nd Edition 1976. </paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number> In the diagnostic tests, a serum sample from the person to be investigated is brought into contact with the protein chains of one or more proteins or glycoproteins (which can be expressed in eukaryotic cell lines), or parts thereof, which originate from MVP-5180/91 (SEQ ID NO:56). Test processes which are preferred include immunofluorescence or immunoenzymatic test processes (e.g. ELISA or immunoblot). </paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> In the immunoenzymatic tests (ELISA), antigen originating from MVP-5180/91 (SEQ ID NO:56) or a variant thereof, for example, can be bound to the walls of microtiter plates. The dosage used in this context depends to an important degree on the test system and the treatment of the microtiter plates. Serum or dilutions of serum deriving from the person to be investigated are then added to the wells of the microtiter plates. After a predetermined incubation time, the plate is washed and specific immunocomplexes are detected by antibodies which bind specifically to human immunoglobulins and which had previously been linked to an enzyme, for example horseradish peroxidase, alkaline phosphatase, etc., or to enzyme-labeled antigen. These enzymes are able to convert a colorless substrate into a strongly colored product, and the presence of specific anti-HIV antibodies can be gathered from the strength of the coloration. A further option for using the virus according to the invention in test systems is its use in Western blots. </paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> Even if the preparation of vaccines against immunodeficiency diseases is proving to be extremely difficult, this virus, too, or parts thereof, i.e. immunodominant epitopes and inducers of cellular immunity, or antigens prepared by genetic manipulation, can still be used for developing and preparing vaccines. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 1 </heading>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number> The immunodeficiency virus according to the invention, MVP-5180/91 (SEQ ID NO:56), was isolated from the blood of a female patient exhibiting signs of immune deficiency. To do this, peripheral mononuclear cells (peripheral blood lymphocytes, PBL) and peripheral lymphocytes from the blood (PBL) of a donor who was not infected with HIV were stimulated with phytohemagglutinin and maintained in culture. For this purpose, use was made of the customary medium RPMI 1640 containing 10% fetal calf serum. The culture conditions are described in Landay A. et al., J. Inf. Dis., 161 (1990) pp. 706-710. The formation of giant cells was then observed under the microscope. The production of HIV viruses was ascertained by determining the p 24 antigen using the test which can be purchased from Abbott. An additional test for determining the growth of the viruses consisted of the test using particle-bound reverse transcriptase (Eberle J., Seibl R., J. Virol. Methods 40, 1992, pp. 347-356). The growth of the viruses was therefore determined once or twice a week on the basis of the enzymatic activities in the culture supernatant, in order to monitor virus production. New donor lymphocytes were added once a week. </paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> Once it was possible to observe HIV virus multiplication, fresh peripheral lymphocytes from the blood (PBL) of healthy donors, who were not infected with HIV, were infected with supernatant from the first culture. This step was repeated and the supernatant was then used to infect H 9 and HUT 78 cells. In this way, it was possible to achieve permanent production of the immunodeficiency virus. The virus was deposited with the ECACC under No. V 920 92 318. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 2 </heading>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> So-called Western blot or immunoblot is currently a standard method for detecting HIV infections. Various sera were examined in accordance with the procedure described by G&uuml;rtler et al. in J. Virol. Meth. 15 (1987) pp. 11-23. In doing this, sera from German patients were compared with sera which had been obtained from African patients. The following results were obtained:  
<table-cwu id="TABLE-US-00004">
<number>4</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="84PT" align="left"/>
<colspec colname="2" colwidth="63PT" align="left"/>
<colspec colname="3" colwidth="56PT" align="left"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Virus type</entry>
<entry>German sera</entry>
<entry>African sera</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>HIV-1, virus</entry>
<entry>strong reaction</entry>
<entry>strong reaction</entry>
</row>
<row>
<entry></entry>
<entry>isolated from</entry>
<entry></entry>
<entry>using gp 41</entry>
</row>
<row>
<entry></entry>
<entry>German patients</entry>
</row>
<row>
<entry></entry>
<entry>MVP-5180/91 (SEQ ID</entry>
<entry>no reaction to</entry>
<entry>strong reaction</entry>
</row>
<row>
<entry></entry>
<entry>NO:56)</entry>
<entry>weak reaction</entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry>using gp 41</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number> The results presented above demonstrate that a virus of the HIV-1 type isolated from German patients may possibly, if used for detecting HIV infections, fail to provide unambiguous results if the patient was infected with a virus corresponding to MVP-5180/91 (SEQ ID NO:56) according to the invention. It is assumed here that those viruses can be detected using the virus according to the invention which possess at least about 85% homology, based on the total genome, with the virus according to the invention. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 3 </heading>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number> Further Western blots were carried out in accordance with the procedure indicated in Example 2. The results are presented in the enclosed <cross-reference target="DRAWINGS">FIG. 3</cross-reference>. In this test, the viral protein of the immunodeficiency virus MVP-5180/91 (SEQ ID NO:56) according to the invention, in the one case, and the viral protein of an HIV-1 type virus (MVP-899), in the other, was fractionated by gel electrophoresis and then transferred to cellulose filters. These filter strips were incubated with the sera from different patients and the specific antibodies were then rendered visible by a color reaction. The left half of the figure with the heading MVP-5180 shows the immunodeficiency virus according to the invention. The right half of the figure shows a virus (MVP-899), which is an HIV-1 virus, isolated from a German donor. </paragraph>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> In <cross-reference target="DRAWINGS">FIG. 3</cross-reference>, the same sera (from German patients) were in each case reacted with two respective filter strips, the numbers 8 and 26; 9 and 27; 10 and 28; 11 and 29; 12 and 30; 13 and 31; 14 and 32; 15 and 33, and 16 and 34 indicating the same sera. Sera from African patients were employed in the Western blots having the numbers 17 and 18. The numbers on the right hand margins indicate the approximate molecular weights in thousands (KD). </paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 3</cross-reference> shows clearly that sera from German patients only react very weakly with the immunodeficiency virus according to the invention in a Western blot using gp 41. By contrast, sera from African patients react very strongly with the immunodeficiency virus according to the invention. <cross-reference target="DRAWINGS">FIG. 3</cross-reference> makes it clear, therefore, that when the immunodeficiency virus according to the invention is used those immunodeficiency infections can be detected which only yield questionable, i.e. not unambiguously positive, results when an HIV-1 or HIV-2 virus is used. This option for detection can be of far-reaching diagnostic importance since, in those cases in which only questionable results are obtained in a Western blot, it cannot be established with unambiguous certainty whether an infection with an immunodeficiency virus is present. However, if the immunodeficiency virus according to the invention can be used to assign such questionable results to an infection with a virus of the type according to the invention, this then represents a substantial diagnostic advance. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 4 </heading>
<paragraph id="P-0053" lvl="0"><number>&lsqb;0053&rsqb;</number> DNA isolation, amplification and structural characterization of sections of the genome of the HIV isolate MVP-5180/91 (SEQ ID NO:56). </paragraph>
<paragraph id="P-0054" lvl="0"><number>&lsqb;0054&rsqb;</number> Genomic DNA from HUT 78 cells infected with MVP-5180/91 (SEQ ID NO:56) was isolated by standard methods. </paragraph>
<paragraph id="P-0055" lvl="0"><number>&lsqb;0055&rsqb;</number> In order to characterize regions of the genome of the isolate MVP-5180/91 (SEQ ID NO:56), PCR (polymerase chain reaction) experiments were carried out using a primer pair from the region of the coat protein gp 41. The PCR experiments were carried out in accordance with the method of Saiki et al. (Saiki et al., Science 239: 487-491, 1988) using the following modifications: for the amplification of regions of HIV-specific DNA, 5 &mgr;l of genomic DNA from HUT 78 cells infected with MVP-5180/91 (SEQ ID NO:56) were pipetted into a 100 &mgr;l reaction mixture (0.25 mM DNTP, in each case 1 &mgr;m primer 1 and primer 2, 10 mM Tris HCl, pH 8.3, 50 mM KCl, 1.5 MgCl<highlight><subscript>2</subscript></highlight>, 0.001% gelatin, 2.5 units of Taq polymerase (Perkin Elmer)), and amplification was then carried out in accordance with the following temperature program: 1. initial denaturation: 3&prime; 95&deg; C., 2. amplification: 90&Prime; 94&deg; C., 60&Prime; 56&deg; C., 90&Prime;, 72&deg; C. (30 cycles). </paragraph>
<paragraph id="P-0056" lvl="0"><number>&lsqb;0056&rsqb;</number> The primers used for the PCR and for nucleotide sequencing were synthesized on a Biosearch 8750 oligonucleotide synthesizer. </paragraph>
<paragraph id="P-0057" lvl="1"><number>&lsqb;0057&rsqb;</number> Primer 1 (SEQ ID NO:35): AGC AGC AGG AAG CAC TAT GG (coordinates from HIV-1 isolate HXB2: bases 7795-7814, corresponds to primer sk 68) (SEQ ID NO:21) </paragraph>
<paragraph id="P-0058" lvl="1"><number>&lsqb;0058&rsqb;</number> Primer 2 (SEQ ID NO:36): GAG TTT TCC AGA GCA ACC CC (coordinates from HIV-1 isolate HXB2: bases 8003-8022, corresponds to primer env b (SEQ ID NO:20). </paragraph>
<paragraph id="P-0059" lvl="0"><number>&lsqb;0059&rsqb;</number> The amplified DNA was fractionated on a 3% &ldquo;Nusieve&rdquo; agarose gel (from Biozyme) and the amplified fragment was then cut out and an equal volume of buffer (1*TBE (0.09 M Tris borate, 0.002 M EDTA, pH 8.0) was added to it. After incubating the DNA/agarose mixture at 70&deg; C. for 10 minutes, and subsequently extracting with phenol, the DNA was precipitated from the aqueous phase by adding 1/10 vol of 3 M NaAc, pH 5.5, and 2 vol of ethanol and storing at &minus;20&deg; C. for 15&prime;, and then subsequently pelleted in a centrifuge (Eppendorf) (13,000 rpm, 10&prime;, 4&deg; C.). The pelleted DNA was dried and taken up in water, and then, after photometric determination of the DNA concentration at 260 nm in a spectrophotometer (Beckman), sequenced by the Sanger method (F. Sanger, Proc. Natl. Acad,. Sci., 74: 5463, 1977). Instead of sequencing with Klenow DNA polymerase, the sequencing reaction was carried out using a kit from Applied Biosystems (&ldquo;Taq dye deoxy terminator cycle sequencing&rdquo;, order No.: 401150). Primer 1 (SEQ ID NO:35) or primer 2 (SEQ ID NO:36) (in each case 1 &mgr;M) was employed as primers in separate sequencing reactions. The sequencing reaction was analysed on a 373A DNA sequencing apparatus (Applied Biosystems) in accordance with the instructions of the apparatus manufacturer. </paragraph>
<paragraph id="P-0060" lvl="0"><number>&lsqb;0060&rsqb;</number> The nucleotide sequence of the amplified DNA region, and the amino acid sequence deduced from it, are presented in Table 1. Table 1 includes the DNA sequences SEQ ID NO:37 and SEQ ID NO:38, as well as amino acid SEQ ID NO:39. The top line in Table 1 corresponds to SEQ ID NO:37, the middle line corresponds to SEQ ID NO:38, and the bottom line corresponds to the amino acid SEQ ID NO:39.  
<table-cwu id="TABLE-US-00005">
<number>5</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="259PT" align="left"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 1</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>GCGCAGCGGCAACAGCGCTGACGGTACGGACCCACAGTGTACTGAAGGGTATAGTGCAAC</entry>
</row>
<row>
<entry>----------&plus;--------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
</row>
<row>
<entry>CGCGTCGCCGTTGTCGCGACTGCCATGCCTGGGTGTCACATGACTTCCCATATCACGTTG</entry>
</row>
<row>
<entry>&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;T&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;T&emsp;&emsp;V&emsp;&emsp;R&emsp;&emsp;T&emsp;&emsp;H&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;L&emsp;&emsp;K&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;V&emsp;&emsp;Q&emsp;&emsp;Q</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>AGCAGGACAACCTGCTGAGAGCGATACAGGCCCAGCAACACTTGCTGAGGTTATCTGTAT</entry>
</row>
<row>
<entry>---------&plus;--------&plus;---------&plus;-----&plus;----&plus;---------&plus;---------&plus;</entry>
</row>
<row>
<entry>TCGTCCTGTTGGACGACTCTCGCTATGTCCGGGTCGTTGTGAACGACTCCAATAGACATA</entry>
</row>
<row>
<entry>&emsp;&emsp;Q&emsp;&emsp;D&emsp;&emsp;N&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;A&emsp;&emsp;I&emsp;&emsp;Q&emsp;&emsp;A&emsp;&emsp;Q&emsp;&emsp;Q&emsp;&emsp;H&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;W</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>GGGGTATTAGACAACTCCGAGCTCGCCTGCAAGCCTTAGAAACCCTTATACAGAATCAGC</entry>
</row>
<row>
<entry>---------&plus;--------&plus;----------&plus;---------&plus;---------&plus;---------&plus;</entry>
</row>
<row>
<entry>CCCCATAATCTGTTGAGGCTCGAGCGGACGTTCGGAATCTTTGGGAATATGTCTTAGTCG</entry>
</row>
<row>
<entry>&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;R&emsp;&emsp;Q&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;A&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;Q&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;E&emsp;&emsp;T&emsp;&emsp;L&emsp;&emsp;I&emsp;&emsp;Q&emsp;&emsp;N&emsp;&emsp;Q&emsp;&emsp;Q</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>AACGCCTAAACCTAT</entry>
</row>
<row>
<entry>---------&plus;-----&emsp;&emsp;195</entry>
</row>
<row>
<entry>TTGCGGATTTGGATA</entry>
</row>
<row>
<entry>&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;N&emsp;&emsp;L</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 5 </heading>
<paragraph id="P-0061" lvl="0"><number>&lsqb;0061&rsqb;</number> The found nucleotide sequence from Table 1 was examined for homologous sequences in the GENEBANK database (Release 72, June 1992) using the GCG computer program (Genetic Computer Group, Inc., Wisconsin USA, Version 7.1, March 1992). Most of the nucleotide sequences of immunodeficient viruses of human origin and of isolates from primates known by July 1992 are contained in this database. </paragraph>
<paragraph id="P-0062" lvl="0"><number>&lsqb;0062&rsqb;</number> The highest homology shown by the nucleotide sequence from Table 1, of 66%, is to a chimpanzee isolate. The highest homology shown by the investigated DNA sequence from MVP-5180/91 (SEQ ID NO:56) to HIV-1 isolates is 64%. The DNA from Table 1 is 56% homologous to HIV-2 isolates. Apart from the chimpanzee isolate sequence, the best homology between the nucleotide sequence from Table 1 (SEQ ID NO:37; SEQ ID NO:38) and segments of DNA from primate isolates (SIV: simian immunodeficiency virus) is found with a DNA sequence encoding a part of the coat protein region from the SIV isolate (African long-tailed monkey) TYO-1. The homology is 61.5%. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 6 </heading>
<paragraph id="P-0063" lvl="0"><number>&lsqb;0063&rsqb;</number> The found amino acid sequence from Table 1 (SEQ ID NO:39) was examined for homologous sequences in the SWISSPROT protein database (Release 22, June 1992) using the GCG computer program. Most of the protein sequences of immunodeficiency viruses of human origin and of isolates from primates known by June 1992 are contained in this database. </paragraph>
<paragraph id="P-0064" lvl="0"><number>&lsqb;0064&rsqb;</number> The highest homology shown by the amino acid sequence from Table 1 (SEQ ID NO:39), of 62.5%, is to a segment of coat protein from the abovementioned chimpanzee isolate. The best homology among HIV-1 coat proteins to the amino acid sequence from Table 1 (SEQ ID NO:39) is found in the isolate HIV-1 Mal. The homology is 59%. The highest homology of the amino acid sequence from Table 1 (SEQ ID NO:39) to HIV-2 coat proteins is 52% (isolate HIV-2 Rod). Since HIV-1 and HIV-2 isolates, themselves, are at most only 64% identical in the corresponding protein segment, the MVP-5180/91 (SEQ ID NO:56) isolate appears to be an HIV variant which clearly differs structurally from HIV-1 and HIV-2 and thus represents an example of an independent group of HIV viruses. </paragraph>
<paragraph id="P-0065" lvl="0"><number>&lsqb;0065&rsqb;</number> The amino acid sequence of the amplified region of DNA (Table 1; SEQ ID NO:39) from the HIV isolate MVP-5180/91 (SEQ ID NO:56) overlaps an immunodiagnostically important region of the coat protein gp 41 from HIV-1 (amino acids 584-618*) (Table 2, which includes SEQ ID NO:61 as the top line and SEQ ID NO:63 as the bottom line) (Gnann et al., J. Inf. Dis. 156: 261-267, 1987; Norrby et al., Nature, 329: 248-250, 1987). </paragraph>
<paragraph id="P-0066" lvl="0"><number>&lsqb;0066&rsqb;</number> Corresponding amino acid regions from the coat proteins of HIV-2 and SIV are likewise immunodiagnostically conserved (Gnann et al., Science, pp. 1346-1349, 1987). Thus, peptides from this coat protein region of HIV-1 and HIV-2 are employed as solid-phase antigens in many commercially available HIV-1/2 antibody screening tests. Approximately 99% of the anti-HIV-1 and anti-HIV-2 positive sera can be identified by them. </paragraph>
<paragraph id="P-0067" lvl="0"><number>&lsqb;0067&rsqb;</number> The amino acid region of the MVP-5180/91 coat protein (Table 1) could be of serodiagnostic importance owing to the overlap with the immunodiagnostically important region from gp 41. This would be the case particularly if antisera from HIV-infected patients failed to react positively with any of the commercially available antibody screening tests. In these cases, the infection could be with a virus which was closely related to MVP-5180/91 (SEQ ID NO:56).  
<table-cwu id="TABLE-US-00006">
<number>6</number>
<table frame="none" colsep="0" rowsep="0" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 2</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>(includes SEQ ID NO:61 as the top line</entry>
</row>
<row>
<entry>and SEQ ID NO:63 as the bottom line)</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="203PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;.&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;.&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;.&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;.</entry>
</row>
<row>
<entry></entry>
<entry>........RILAVERYLKDQQLLGIWGCSGKLICTTAVPWNAS</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&verbar;:&emsp;&verbar;:&verbar;&emsp;.:.:&verbar;&verbar;&emsp;&verbar;.:</entry>
</row>
<row>
<entry></entry>
<entry>WGIRQLRARLQALETLIQNQQRLNL..................</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 7 </heading>
<paragraph id="P-0068" lvl="0"><number>&lsqb;0068&rsqb;</number> DNA isolation, amplification and structural characterization of genome segments from the HIV isolate MVP-5180/91 (SEQ ID NO:56) (encoding gp 41). </paragraph>
<paragraph id="P-0069" lvl="0"><number>&lsqb;0069&rsqb;</number> Genomic DNA from MVP-5180/91 (SEQ ID NO:56)-infected HUT 78 cells was isolated as described. </paragraph>
<paragraph id="P-0070" lvl="0"><number>&lsqb;0070&rsqb;</number> In order to characterize genomic regions of the isolate MVP-5180/91, PCR (polymerase chain reaction) experiments were carried out using primer pairs from the gp 41 coat protein region. PCR (Saiki et al., Science 239: 487-491, 1988) and inverse PCR (Triglia et al., Nucl. Acids, Res. 16: 8186, 1988) were carried out with the following modifications: </paragraph>
<paragraph id="P-0071" lvl="0"><number>&lsqb;0071&rsqb;</number> 1. PCR </paragraph>
<paragraph id="P-0072" lvl="0"><number>&lsqb;0072&rsqb;</number> For the amplification of HIV-specific DNA regions, 5 &mgr;l (218 &mgr;g/ml) of genomic DNA from MVP-5180/91-infected HUT 78 cells were pipetted into a 100 &mgr;l reaction mixture (0.25 mM dNTP, in each case 1 &mgr;m primer 163env (SEQ ID NO:40) and primer envend (SEQ ID NO:41), 10 mM Tris HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<highlight><subscript>2</subscript></highlight>, 0.001% gelatin, 2.5 units of Taq polymerase (Perkin Elmer)), and amplification was then carried out in accordance with the following temperature program: 1. initial denaturation: 3 min. 95&deg; C., 2. amplification: 90 sec. 94&deg; C., 60 sec. 56&deg; C., 90 sec. 72&deg; C. (30 cycles). </paragraph>
<paragraph id="P-0073" lvl="0"><number>&lsqb;0073&rsqb;</number> 2. Inverse PCR </paragraph>
<paragraph id="P-0074" lvl="0"><number>&lsqb;0074&rsqb;</number> The 5&prime; region of gp 41 (N terminus) and the 3&prime; sequence of gp 120 were amplified by means of &ldquo;inverse PCR&rdquo;. For this, 100 &mgr;l of a genomic DNA preparation (218 &mgr;g/ml) from MVP-5180/91-infected HUT 78 cells were digested at 37&deg; C. for 1 hour in a final volume of 200 &mgr;l using 10 units of the restriction endonuclease Sau3a. The DNA was subsequently extracted with phenol and then precipitated using sodium acetate (final concentration 300 mM) and 2.5 volumes of ethanol, with storage at &minus;70&deg; C. for 10 min, and then centrifuged down in an Eppendorf centrifuge; the pellet was then dried and resuspended in 890 &mgr;l of distilled water. Following addition of 100 &mgr;l of ligase buffer (50 mM Tris HCl, pH 7.8, 10 mM MgCl<highlight><subscript>2</subscript></highlight>, 10 mM DTT, 1 mM ATP, 25 &mgr;g/ml bovine serum albumin) and 10 &mgr;l of T4 DNA ligase (from Boehringer, Mannheim), the DNA fragments were ligated at room temperature for 3 hours and then extracted with phenol once again and precipitated with sodium acetate and ethanol as above. After centrifuging down and drying, the DNA was resuspended in 40 &mgr;l of distilled water and digested for 1 hour with 10 units of the restriction endonuclease SacI (from Boehringer, Mannheim). 5 &mgr;l of this mixture were then employed in a PCR experiment as described under &ldquo;1. PCR&rdquo;. The primers 168i (SEQ ID NO:42) and 169i (SEQ ID NO:43) were used for the inverse PCR in place of primers 163env (SEQ ID NO:40) and envend (SEQ ID NO:41). </paragraph>
<paragraph id="P-0075" lvl="0"><number>&lsqb;0075&rsqb;</number> The primers 163env (SEQ ID NO:40), 168i (SEQ ID NO:42) and 169i (SEQ ID NO:43) were selected from that part of the sequence of the HIV isolate MVP-5180 (SEQ ID NO:56) which had already been elucidated (Example 4). </paragraph>
<paragraph id="P-0076" lvl="0"><number>&lsqb;0076&rsqb;</number> The primers used for the PCR/inverse PCR and the nucleotide sequencing were synthesized on a Biosearch 8750 oligonucleotide synthesizer, with the primers having the following sequences: </paragraph>
<paragraph id="P-0077" lvl="1"><number>&lsqb;0077&rsqb;</number> Primer 163env (SEQ ID NO:40): </paragraph>
<paragraph id="P-0078" lvl="2"><number>&lsqb;0078&rsqb;</number> 5&prime; CAG AAT CAG CAA CGC CTA AAC C 3&prime;</paragraph>
<paragraph id="P-0079" lvl="1"><number>&lsqb;0079&rsqb;</number> Primer envend (SEQ ID NO:41): </paragraph>
<paragraph id="P-0080" lvl="2"><number>&lsqb;0080&rsqb;</number> 5&prime; GCC CTG TCT TAT TCT TCT AGG 3&prime;</paragraph>
<paragraph id="P-0081" lvl="3"><number>&lsqb;0081&rsqb;</number> (position from HIV-1 isolate BH10: bases 8129-8109) </paragraph>
<paragraph id="P-0082" lvl="1"><number>&lsqb;0082&rsqb;</number> Primer 168i (SEQ ID NO:42): </paragraph>
<paragraph id="P-0083" lvl="2"><number>&lsqb;0083&rsqb;</number> 5&prime; GCC TGC AAG CCT TAG AAA CC 3&prime;</paragraph>
<paragraph id="P-0084" lvl="1"><number>&lsqb;0084&rsqb;</number> Primer 169i (SEQ ID NO:43): </paragraph>
<paragraph id="P-0085" lvl="2"><number>&lsqb;0085&rsqb;</number> 5&prime; GCA CTA TAC CCT TCA GTA CAC TG 3&prime;</paragraph>
<paragraph id="P-0086" lvl="0"><number>&lsqb;0086&rsqb;</number> The amplified DNA was fractionated on a 3% &ldquo;Nusieve&rdquo; agarose gel (from Biozyme) and the amplified fragment was then cut out and an equal volume of buffer (1*TBE (0.09 M Tris borate, 0.002 M EDTA, pH 8.0)) was added to it. After incubating the DNA/agarose mixture at 70&deg; C. for 10 minutes, and subsequent phenol extraction, the DNA was precipitated from the aqueous phase by adding 1/10 vol of 3 M NaAc, pH 5.5, and 2 vol of ethanol, and storing at &minus;20&deg; C. for 15&prime;, and then pelleted in an Eppendorf centrifuge (13,000 rpm, 10&prime;, 4&deg; C.). The pelleted DNA was dried and then taken up in water and sequenced by the method of Sanger (F. Sanger, Proc. Natl. Acad. Sci., 74: 5463, 1977) following photometric determination of the DNA concentration at 260 nm in a spectrophotometer (from Beckman). Instead of sequencing with Klenow DNA polymerase, the sequencing reaction was carried out using a kit from Applied Biosystems (&ldquo;Taq dye deoxy terminator cycle sequencing&rdquo;, order No.: 401150). Primer 163env (SEQ ID NO:40) or primer envend (SEQ ID NO:41) (in each case 1 &mgr;M) was employed as the primer in separate sequencing reactions. The amplified DNA from the inverse PCR experiment was sequenced using primers 168i (SEQ ID NO:42) and 169i (SEQ ID NO:43). The sequencing reaction was analysed on an Applied Biosystems 373A DNA sequencing apparatus in accordance with the instructions of the apparatus manufacturer. </paragraph>
<paragraph id="P-0087" lvl="0"><number>&lsqb;0087&rsqb;</number> The nucleotide sequence of the amplified DNA region, and the amino acid sequence deduced from it, are presented in Table 3. Table 3 includes DNA sequences SEQ ID NO:44 and SEQ ID NO:45, as well as amino acid sequence SEQ ID NO:46. In Table 3, the top line corresponds to SEQ ID NO:44, the middle line corresponds to SEQ ID NO:45, and the bottom line represents amino acid sequence SEQ ID NO:46.  
<table-cwu id="TABLE-US-00007">
<number>7</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="21PT" align="char"/>
<colspec colname="2" colwidth="259PT" align="left"/>
<colspec colname="3" colwidth="21PT" align="char"/>
<thead>
<row>
<entry namest="1" nameend="3" align="center">TABLE 3</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>AAATGTCAAGACCAATAATAAACATTCACACCCCTCACAGGGAAAAAAGAGCAGTAGGAT</entry>
<entry></entry>
</row>
<row>
<entry>1</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>60</entry>
</row>
<row>
<entry></entry>
<entry>TTTACAGTTCTGGTTATTATTTGTAAGTGTGGGGAGTGTCCCTTTTTTCTCGTCATCCTA</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;M&emsp;&emsp;S&emsp;&emsp;R&emsp;&emsp;P&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;N&emsp;&emsp;I&emsp;&emsp;H&emsp;&emsp;T&emsp;&emsp;P&emsp;&emsp;H&emsp;&emsp;R&emsp;&emsp;E&emsp;&emsp;K&emsp;&emsp;R&emsp;&verbar;A&emsp;&emsp;V&emsp;&emsp;G&emsp;&emsp;L</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;gp120&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;gp41</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>TGGGAATGCTATTCTTGGGGGTGCTAAGTGcAGCAGGTAGCACTATGGGCGCAGCGGCAA</entry>
</row>
<row>
<entry>61</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>120</entry>
</row>
<row>
<entry></entry>
<entry>ACCCTTACGATAAGAACCCCCACGATTCACGTCGTCCATCGTGATACCCGCGTCGCCGTT</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;G&emsp;&emsp;M&emsp;&emsp;L&emsp;&emsp;F&emsp;&emsp;L&emsp;&emsp;G&emsp;&emsp;V&emsp;&emsp;L&emsp;&emsp;S&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;G&emsp;&emsp;S&emsp;&emsp;T&emsp;&emsp;M&emsp;&emsp;G&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;T</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>CAGCGCTGACGGTACGGACCCACAGTGTACTGAAGGGTATAGTGCAACAGCAGGACAACC</entry>
</row>
<row>
<entry>121</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>180</entry>
</row>
<row>
<entry></entry>
<entry>GTCGCGACTGCCATGCCTGGGTGTCACATGACTTCCCATATCACGTTGTCGTCCTGTTGG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;T&emsp;&emsp;V&emsp;&emsp;R&emsp;&emsp;T&emsp;&emsp;H&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;L&emsp;&emsp;K&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;V&emsp;&emsp;Q&emsp;&emsp;Q&emsp;Q&emsp;&emsp;D&emsp;&emsp;N&emsp;&emsp;L</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>TGCTGAGAGCGATACAGGCCCAGCAACACTTGCTGAGGTTATCTGTATGGGGTATTAGAC</entry>
</row>
<row>
<entry>181</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>240</entry>
</row>
<row>
<entry></entry>
<entry>ACGACTCTCGCTATGTCCGGGTCGTTGTGAACGACTCCAATAGACATACCCCATAATCTG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;A&emsp;&emsp;I&emsp;&emsp;Q&emsp;&emsp;A&emsp;&emsp;Q&emsp;&emsp;Q&emsp;&emsp;H&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;W&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;R&emsp;&emsp;Q</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>AACTCCGAGCTCGCCTGCAAGCCTTAGAAACCCTTATACAGAATCAGCAACGCCTAAACC</entry>
</row>
<row>
<entry>241</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>300</entry>
</row>
<row>
<entry></entry>
<entry>TTGAGGCTCGAGCGGACGTTCGGAATCTTTGGGAATATGTCTTAGTCGTTGCGGATTTGG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;A&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;Q&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;E&emsp;&emsp;T&emsp;&emsp;L&emsp;&emsp;I&emsp;&emsp;Q&emsp;&emsp;N&emsp;&emsp;Q&emsp;&emsp;Q&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;N&emsp;&emsp;L</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>TATGGGGCTGTAAAGGAAAACTAATCTGTTACACATCAGTAAAATGGAACACATCATGGT</entry>
</row>
<row>
<entry>301</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>360</entry>
</row>
<row>
<entry></entry>
<entry>ATACCCCGACATTTCCTTTTGATTAGACAATGTGTAGTCATTTTACCTTGTGTAGTACCA</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;W&emsp;&emsp;G&emsp;&emsp;C&emsp;&emsp;K&emsp;&emsp;G&emsp;&emsp;K&emsp;&emsp;L&emsp;&emsp;I&emsp;&emsp;C&emsp;&emsp;Y&emsp;&emsp;T&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;K&emsp;&emsp;W&emsp;&emsp;N&emsp;&emsp;T&emsp;&emsp;S&emsp;&emsp;W&emsp;&emsp;S</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>CAGGAGGATATAATGATGACAGTATTTGGGACAACCTTACATGGCAGCAATGGGACCAAC</entry>
</row>
<row>
<entry>361</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>420</entry>
</row>
<row>
<entry></entry>
<entry>GTCCTCCTATATTACTACTGTCATAAACCCTGTTGGAATGTACCGTCGTTACCCTGGTTG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;G&emsp;&emsp;G&emsp;&emsp;Y&emsp;&emsp;N&emsp;&emsp;D&emsp;&emsp;D&emsp;&emsp;S&emsp;&emsp;I&emsp;&emsp;W&emsp;&emsp;D&emsp;&emsp;N&emsp;&emsp;L&emsp;&emsp;T&emsp;&emsp;W&emsp;&emsp;Q&emsp;&emsp;Q&emsp;&emsp;W&emsp;&emsp;D&emsp;&emsp;Q&emsp;&emsp;H</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>ACATAAACAATGTAAGCTCCATTATATATGATGAAATACAAGCAGCACAAGACCAACAGG</entry>
</row>
<row>
<entry>421</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>480</entry>
</row>
<row>
<entry></entry>
<entry>TGTATTTGTTACATTCGAGGTAATATATACTACTTTATGTTCGTCGTGTTCTGGTTGTCC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;I&emsp;&emsp;N&emsp;&emsp;N&emsp;&emsp;V&emsp;&emsp;S&emsp;&emsp;S&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;Y&emsp;&emsp;D&emsp;&emsp;E&emsp;&emsp;I&emsp;&emsp;Q&emsp;&emsp;A&emsp;&emsp;A&emsp;&emsp;Q&emsp;&emsp;D&emsp;&emsp;Q&emsp;&emsp;Q&emsp;&emsp;E</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>AAAAGAATGTAAAAGCATTGTTGGAGCTAGATGAATGGGCCTCTCTTTGGAATTGGTTTG</entry>
</row>
<row>
<entry>481</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>540</entry>
</row>
<row>
<entry></entry>
<entry>TTTTCTTACATTTTCGTAACAACCTCGATCTACTTACCCGGAGAGAAACCTTAACCAAAC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;K&emsp;&emsp;N&emsp;&emsp;V&emsp;&emsp;K&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;E&emsp;&emsp;L&emsp;&emsp;D&emsp;&emsp;E&emsp;&emsp;W&emsp;&emsp;A&emsp;&emsp;S&emsp;&emsp;L&emsp;&emsp;W&emsp;&emsp;N&emsp;&emsp;W&emsp;&emsp;F&emsp;&emsp;D</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>ACATAACTAAATGGTTGTGGTATATAAAAATAGCTATAATCATAGTGGGAGCACTAATAG</entry>
</row>
<row>
<entry>541</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>600</entry>
</row>
<row>
<entry></entry>
<entry>TGTATTGATTTACCAACACCATATATTTTTATCGATATTAGTATCACCCTCGTGATTATC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;I&emsp;&emsp;T&emsp;&emsp;K&emsp;&emsp;W&emsp;&emsp;L&emsp;&emsp;W&emsp;&emsp;Y&emsp;&emsp;I&emsp;&emsp;K&emsp;&emsp;I&emsp;&emsp;A&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;V&emsp;&emsp;G&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;I&emsp;&emsp;G</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>GTATAAGAGTTATCATGATAGTACTTAATCTAGTGAAGAACATTAGGCAGGGATATCAAC</entry>
</row>
<row>
<entry>601</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>660</entry>
</row>
<row>
<entry></entry>
<entry>CATATTCTCAATAGTACTATCATGAATTAGATCACTTCTTGTAATCCGTCCCTATAGTTG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;I&emsp;&emsp;R&emsp;&emsp;V&emsp;&emsp;I&emsp;&emsp;M&emsp;&emsp;I&emsp;&emsp;V&emsp;&emsp;L&emsp;&emsp;N&emsp;&emsp;L&emsp;&emsp;V&emsp;&emsp;K&emsp;&emsp;N&emsp;&emsp;I&emsp;&emsp;R&emsp;&emsp;Q&emsp;&emsp;G&emsp;&emsp;Y&emsp;&emsp;Q&emsp;&emsp;P</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>CCCTCTCGTTGCAGATCCCTGTCCCACACCGGCAGGAAGCAGAAACGCCAGGAAGAACAG</entry>
</row>
<row>
<entry>661</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>720</entry>
</row>
<row>
<entry></entry>
<entry>GGGAGAGCAACGTCTAGGGACAGGGTGTGGCCGTCCTTCGTCTTTGCGGTCCTTCTTGTC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;L&emsp;&emsp;S&emsp;&emsp;L&emsp;&emsp;Q&emsp;&emsp;I&emsp;&emsp;P&emsp;&emsp;V&emsp;&emsp;P&emsp;&emsp;H&emsp;&emsp;R&emsp;&emsp;Q&emsp;&emsp;E&emsp;&emsp;A&emsp;&emsp;E&emsp;&emsp;T&emsp;&emsp;P&emsp;&emsp;G&emsp;&emsp;R&emsp;&emsp;T&emsp;&emsp;G</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>GAGAAGAAGGTGGAGAAGGAGACAGGCCCAAGTGGACAGCCTTGCCACCAGGATTCTTGC</entry>
</row>
<row>
<entry>721</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>780</entry>
</row>
<row>
<entry></entry>
<entry>CTCTTCTTCCACCTCTTCCTCTGTCCGGGTTCACCTGTCGGAACGGTGGTCCTAAGAACG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;E&emsp;&emsp;E&emsp;&emsp;G&emsp;&emsp;G&emsp;&emsp;E&emsp;&emsp;G&emsp;&emsp;D&emsp;&emsp;R&emsp;&emsp;P&emsp;&emsp;K&emsp;&emsp;W&emsp;&emsp;T&emsp;&emsp;A&emsp;&emsp;L&emsp;&emsp;P&emsp;&emsp;P&emsp;&emsp;G&emsp;&emsp;F&emsp;&emsp;L&emsp;&emsp;Q</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>AACAGTTGTACACGGATCTCAGGACAATAATCTTGTGGACTTACCACCTCTTGAGCAACT</entry>
</row>
<row>
<entry>781</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>840</entry>
</row>
<row>
<entry></entry>
<entry>TTGTCAACATGTGCCTAGAGTCCTGTTATTAGAACACCTGAATGGTGGAGAACTCGTTGA</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;Q&emsp;&emsp;L&emsp;&emsp;Y&emsp;&emsp;T&emsp;&emsp;D&emsp;&emsp;L&emsp;&emsp;R&emsp;&emsp;T&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;L&emsp;&emsp;W&emsp;&emsp;T&emsp;&emsp;Y&emsp;&emsp;H&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;S&emsp;&emsp;N&emsp;&emsp;L</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>TAATATCAGGGATCCGGAGGCTGATCGACTACCTGGGACTGGGACTGTGGATCCTGGGAC</entry>
</row>
<row>
<entry>841</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>900</entry>
</row>
<row>
<entry></entry>
<entry>ATTATAGTCCCTAGGCCTCCGACTAGCTGATGGACCCTGACCCTGACACCTAGGACCCTG</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;I&emsp;&emsp;S&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;R&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;I&emsp;&emsp;D&emsp;&emsp;Y&emsp;&emsp;L&emsp;&emsp;G&emsp;&emsp;L&emsp;&emsp;G&emsp;&emsp;L&emsp;&emsp;W&emsp;&emsp;I&emsp;&emsp;L&emsp;&emsp;G&emsp;&emsp;Q</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>AAAAGACAATTGAAGCTTGTAGACTTTGTGGAGCTGTAATGCAATATTGGCTACAAGAAT</entry>
</row>
<row>
<entry>901</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>960</entry>
</row>
<row>
<entry></entry>
<entry>TTTTCTGTTAACTTCGAACATCTGAAACACCTCGACATTACGTTATAACCGATGTTCTTA</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;K&emsp;&emsp;T&emsp;&emsp;I&emsp;&emsp;E&emsp;&emsp;A&emsp;&emsp;C&emsp;&emsp;R&emsp;&emsp;L&emsp;&emsp;C&emsp;&emsp;G&emsp;&emsp;A&emsp;&emsp;V&emsp;&emsp;M&emsp;&emsp;Q&emsp;&emsp;Y&emsp;&emsp;W&emsp;&emsp;L&emsp;&emsp;Q&emsp;&emsp;E&emsp;&emsp;L</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>TGAAAAATAGTGCTACAAACCTGCTTGATACTATTGCAGTGTCAGTTGCCAATTGGACTG</entry>
</row>
<row>
<entry>961</entry>
<entry>---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;---------&plus;</entry>
<entry>1020</entry>
</row>
<row>
<entry></entry>
<entry>ACTTTTTATCACGATGTTTGGACGAACTATGATAACGTCACAGTCAACGGTTAACCTGAC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;K&emsp;&emsp;N&emsp;&emsp;S&emsp;&emsp;A&emsp;&emsp;T&emsp;&emsp;N&emsp;&emsp;L&emsp;&emsp;L&emsp;&emsp;D&emsp;&emsp;T&emsp;&emsp;I&emsp;&emsp;A&emsp;&emsp;V&emsp;&emsp;S&emsp;&emsp;V&emsp;&emsp;A&emsp;&emsp;N&emsp;&emsp;W&emsp;&emsp;T&emsp;&emsp;D</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>ACGGCATCATCTTAGGTCTACAAAGAATAGGACAAGG</entry>
</row>
<row>
<entry>1021</entry>
<entry>---------&plus;---------&plus;---------&plus;-------</entry>
<entry>1057</entry>
</row>
<row>
<entry></entry>
<entry>TGCCGTAGTAGAATCCAGATGTTTCTTATCCTGTTCC</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;G&emsp;&emsp;I&emsp;&emsp;I&emsp;&emsp;L&emsp;&emsp;G&emsp;&emsp;L&emsp;&emsp;Q&emsp;&emsp;R&emsp;&emsp;I&emsp;&emsp;G&emsp;&emsp;Q</entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 8 </heading>
<paragraph id="P-0088" lvl="0"><number>&lsqb;0088&rsqb;</number> The found nucleotide sequence from Table 3 (SEQ ID NO:44; SEQ ID NO:45) was examined for homologous sequences in the GENEBANK database (Release 72, June 1992) using the GCG computer program (Genetic Computer Group, Inc. Wisconsin USA, version 7.1, March 1992). Most of the nucleotide sequences of immunodeficiency viruses of human origin and of isolates from primates known by July 1992 are contained in this database. </paragraph>
<paragraph id="P-0089" lvl="0"><number>&lsqb;0089&rsqb;</number> The highest homology of the nucleotide sequence from Table 3 (SEQ ID NO:44; SEQ ID NO:45) to an HIV-1 isolate is 62%. The DNA from Table 3 is 50% homologous to HIV-2 isolates. </paragraph>
<paragraph id="P-0090" lvl="0"><number>&lsqb;0090&rsqb;</number> The amino acid sequence deduced from the nucleotide sequence from Table 3 (SEQ ID NO:46) was examined for homologous sequences in the SWISSPROT protein database (Release 22, June 1992) using the GCG computer program. Most of the protein sequences of immunodeficiency viruses of human origin and of isolates from primates known by June 1992 are contained in this database. </paragraph>
<paragraph id="P-0091" lvl="0"><number>&lsqb;0091&rsqb;</number> At best, the amino acid sequence from Table 3 (SEQ ID NO:46) is 54% homologous to the corresponding coat protein segment from a chimpanzee isolate CIV (SIVcpz) and 54.5% homologous to the HIV-1 isolate Mal. At best, the amino acid sequence from Table 3 (SEQ ID NO:46) is 34% homologous to HIV-2 coat proteins (isolate HIV-2 D194). </paragraph>
<paragraph id="P-0092" lvl="0"><number>&lsqb;0092&rsqb;</number> If, by contrast, the gp 41 amino acid sequence of HIV-1 is compared with the HIV-1 gp 41 sequence present in the SWISSPROT database, the highest homology is, as expected, almost 100%, and the lowest 78%. </paragraph>
<paragraph id="P-0093" lvl="0"><number>&lsqb;0093&rsqb;</number> These clear structural differences between the sequence region from Table 3 and the corresponding segment from HIV-1 and HIV-2 suggest that isolate MVP-5180/91 (SEQ ID NO:56) is an HIV variant which clearly differs structurally from HIV-1 and HIV-2. It is possible that MVP-5180/91 (SEQ ID NO:56) should be assigned to a separate group of HIV viruses which differ from HIV-1 and HIV-2. </paragraph>
<paragraph id="P-0094" lvl="0"><number>&lsqb;0094&rsqb;</number> The peptide from amino acid 584 to amino acid 618 of the HIV-1 coat protein region (SEQ ID NO:61) is of particular serodiagnostic interest (numbering in accordance with Wain Hobson et al., Cell 40: 9-17, 1985; Gnann et al., J. Inf. Dis. 156: 261-267, 1987; Norrby et al., Nature, 329: 248-250, 1987). Corresponding amino acid regions from the coat proteins of HIV-2 and SIV are likewise immunodiagnostically conserved (Gnann et al., Science, pp. 1346-1349, 1987). Thus, peptides from this coat protein region of HIV-1 and HIV-2 are employed as solid-phase antigens in many commercially available HIV-1/2 antibody screening tests. Using them, approximately 99% of the anti-HIV-1 and anti-HIV-2-positive sera can be identified. </paragraph>
<paragraph id="P-0095" lvl="0"><number>&lsqb;0095&rsqb;</number> The corresponding amino acid region of the MVP-5180/91 coat protein (Table 4), as well as the whole gp 41 of this isolate, could be of serodiagnostic importance, particularly if antisera from HIV-infected patients either did not react at all or only reacted weakly in commercially available antibody screening tests. In these cases, the infection could be due to a virus which is closely related to MVP-5180/91 (SEQ ID NO:56). </paragraph>
<paragraph id="P-0096" lvl="0"><number>&lsqb;0096&rsqb;</number> Table 4 includes SEQ ID NO:61, which is designated as line 1, and also highlights in line 2 the points of difference from the amino acid sequence designated SEQ ID NO:62. Amino acid sequence SEQ ID NO:62 appears in full following Table 4.  
<table-cwu id="TABLE-US-00008">
<number>8</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="203PT" align="left"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center">TABLE 4</entry>
</row>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>1 &emsp;RILAVERYLKDQQLLGIWGCSGKLICTTAVPWNAS</entry>
</row>
<row>
<entry></entry>
<entry>2 &emsp;&ensp;LQ L TLIQN R NL &emsp;K  Y S K T</entry>
</row>
<row>
<entry></entry>
<entry>1 &equals; HIV-1 amino acid sequence from gp 41 &equals; (SEQ ID NO:61)</entry>
</row>
<row>
<entry></entry>
<entry>2 &equals; MVP-5180 sequence from gp 41. Only differences from the</entry>
</row>
<row>
<entry></entry>
<entry>HIV-1 sequence are indicated.</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0097" lvl="0"><number>&lsqb;0097&rsqb;</number> The peptide, which was found with the aid of information deriving from MVP-5180, thus has the amino acid sequence (SEQ ID NO:62): RLQALETLIQNQQRLNLWGCKGKLICYTSVKWNTS. </paragraph>
<paragraph id="P-0098" lvl="0"><number>&lsqb;0098&rsqb;</number> The present invention therefore relates to peptides which can be prepared recombinantly or synthetically and have the sequence indicated above, or a constituent sequence thereof, the constituent sequences having at least 6 consecutive amino acids, preferably 9 and particularly preferably 12 consecutive amino acids. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 9 </heading>
<paragraph id="P-0099" lvl="0"><number>&lsqb;0099&rsqb;</number> Cloning of the whole genome of the HIV isolate MVP-5180 (SEQ ID NO:56) </paragraph>
<paragraph id="P-0100" lvl="0"><number>&lsqb;0100&rsqb;</number> a) Preparation of a genomic library </paragraph>
<paragraph id="P-0101" lvl="0"><number>&lsqb;0101&rsqb;</number> Genomic DNA from MVP-5180-infected HUT 78 cells was isolated as described. </paragraph>
<paragraph id="P-0102" lvl="0"><number>&lsqb;0102&rsqb;</number> 300 &mgr;g of this DNA were incubated for 45 min in a volume of 770 &mgr;l together with 0.24 U of the restriction enzyme Sau3A. The DNA, which was only partially cut in this incubation, was subsequently size-fractionated on a 0.7% agarose gel (low melting agarose, Nusieve) and fragments of between 10 and 21 kb were cut out. The agarose was melted at 70&deg; C. for 10 min and the same volume of buffer (1*TBE, 0.2 M NaCl) was then added to it. Subsequently, after having extracted twice with phenol and once with chloroform, the DNA was precipitated by adding 1/10 vol. of 3 M sodium acetate solution (pH 5.9) and 2.5 vol. of ethanol, and storing at &minus;70&deg; C. for 10 min. The precipitated DNA was centrifuged down and dried and then dissolved in water at a concentration of 1 &mgr;g/pl. </paragraph>
<paragraph id="P-0103" lvl="0"><number>&lsqb;0103&rsqb;</number> The yield of size-fractionated DNA was about 60 &mgr;g. 5 &mgr;g of this DNA were incubated at 37&deg; C. for 20 min in an appropriate buffer together with 1 U of alkaline phosphatase. In this way, the risk of multiple insertions of size-fractionated DNA was reduced by eliminating the 5&prime;-terminal phosphate radical. The phosphatase treatment was stopped by extracting with phenol and the DNA was precipitated as above and then ligated at 15&deg; C. for 12 hours together with 1 &mgr;g of the vector (2 DASH, BamHI-cut, Stratagene No.: 247611) in a total volume of 6 &mgr;l using 2 Weiss units of Lambda T4 ligase. Following completed ligation, the DNA was packaged into phage coats using a packaging kit (Gigapack II Gold, Stratagene No.: 247611) precisely in accordance with the manufacturer&apos;s instructions. </paragraph>
<paragraph id="P-0104" lvl="0"><number>&lsqb;0104&rsqb;</number> b) Radioactive labeling of the DNA probe. </paragraph>
<paragraph id="P-0105" lvl="0"><number>&lsqb;0105&rsqb;</number> The &ldquo;random-primed DNA labeling kit&rdquo; from Boehringer Mannheim (No.: 713 023) was employed for the labeling. The PCR product was labeled which was obtained as described in Example 3 using the primers sk68 (SEQ ID NO:21) and envb (SEQ ID NO:20). 1 &mgr;g of this DNA was denatured by 2*5 min of boiling and subsequent cooling in ice water. 50 mCi &lsqb;a- <highlight><superscript>32</superscript></highlight>p&rsqb;-dCTP (NEN, No.: NEX-053H) were added for the labeling. Other ingredients were added by pipette in accordance with the manufacturer&apos;s instructions. Following a 30 min incubation at 37&deg; C., the DNA, which was now radioactively labeled, was precipitated. </paragraph>
<paragraph id="P-0106" lvl="0"><number>&lsqb;0106&rsqb;</number> c) Screening the phage library </paragraph>
<paragraph id="P-0107" lvl="0"><number>&lsqb;0107&rsqb;</number> 20,000 pfu (plaque-forming units) of the library in 100 &mgr;l of SM buffer (5.8 g of NaCl, 2 g of MgSO<highlight><subscript>4</subscript></highlight>, 50 ml of 1 M Tris, pH 7.5, and 5 ml of a 2% gelatin solution, dissolved in 1l of H<highlight><subscript>2</subscript></highlight>O) were added to 200 &mgr;l of a culture (strain SRB(P2) &lsqb;Stratagene, No.: 247611&rsqb; in LB medium, which contained 10 mM MgSO<highlight><subscript>4 </subscript></highlight>and 0.2% maltose) which had been grown at 30&deg; C. overnight; the phages were adsorbed to the bacteria at 37&deg; C. for 20 min and 7.5 ml of top agarose, which had been cooled to 55&deg; C., was then mixed in and the whole sample was distributed on a pre-warmed LB agar plate of 14 cm diameter. The plaques achieved confluence after about 8 hours. After that, nitrocellulose filters were laid on the plates for a few minutes and were marked asymmetrically. After having been carefully lifted from the plates, the filters were denatured for 2 min (0.5 M NaOH, 1.5 M NaCl) and then neutralized for 5 min (0.5 M Tris, pH 8, 1.5 M NaCl). The filters were subsequently baked at 80&deg; C. for 60 min and could then be hybridized to the probe. For the prehybridization, the filters were incubated at 42&deg; C. for 2-3 h, while shaking, in 15 ml of hybridization solution (50% formamide, 0.5% SDS, 5*SSPE, 5*Denhardt&apos;s solution and 0.1 mg/ml salmon sperm DNA) per filter. The &lsqb;<highlight><superscript>32</superscript></highlight>p&rsqb;-labeled DNA probes were denatured at 100&deg; C. for 2-5 min and then cooled on ice; they were then added to the prehybridization solution and hybridization was carried out at 42&deg; C. for 12 hours. Subsequently, the filters were washed at 60&deg; C., firstly with 2*SSC/0.1% SDS and then with 0.2*SSC/0.1% SDS. After the filters had been dried, hybridization signals were detected using the X-ray film X-OMAT&reg;AR (Kodak). </paragraph>
<paragraph id="P-0108" lvl="0"><number>&lsqb;0108&rsqb;</number> Following elution in SM buffer, those plaques to which it was possible to assign a signal were individually separated in further dilution steps. </paragraph>
<paragraph id="P-0109" lvl="0"><number>&lsqb;0109&rsqb;</number> It was possible to identify the clone described below following screening of 2*10<highlight><superscript>6 </superscript></highlight>plaques. </paragraph>
<paragraph id="P-0110" lvl="0"><number>&lsqb;0110&rsqb;</number> d) Isolation of the phage DNA and subcloning </paragraph>
<paragraph id="P-0111" lvl="0"><number>&lsqb;0111&rsqb;</number> An overnight culture of the host strain SRB (P2) was infected with 10 11 of a phage eluate in SM buffer such that the culture initially grew densely but then lysed after about 6-8 h. Cell remnants were separated off from the lysed culture by centrifuging it twice at 9,000 g for 10 min. Subsequently, the phage were pelleted by centrifugation (35,000 g, 1 h), and then taken up in 700 &mgr;l of 10 mM MgSO<highlight><subscript>4 </subscript></highlight>and extracted with phenol until a protein interface could no longer be seen. The phage DNA was then precipitated and cleaved with the restriction enzyme EcoRI, and the resulting EcoRI fragments were subcloned into the vector Bluescript, KS<highlight><superscript>&minus;</superscript></highlight> (Stratagene, No.: 212208). In all, 4 clones were obtained:  
<table-cwu id="TABLE-US-00009">
<number>9</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="28PT" align="left"/>
<colspec colname="1" colwidth="63PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<colspec colname="3" colwidth="84PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Plasmid</entry>
<entry>Beginning<highlight><superscript>1</superscript></highlight></entry>
<entry>End<highlight><superscript>1</superscript></highlight></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>pSP1</entry>
<entry>&ensp;&emsp;1</entry>
<entry>1785</entry>
</row>
<row>
<entry></entry>
<entry>pSP2</entry>
<entry>1786</entry>
<entry>5833</entry>
</row>
<row>
<entry></entry>
<entry>pSP3</entry>
<entry>5834</entry>
<entry>7415</entry>
</row>
<row>
<entry></entry>
<entry>pSP4</entry>
<entry>7660</entry>
<entry>9793</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="left"><footnote id="FOO-00001"><highlight><superscript>1</superscript></highlight>refers to the total sequence below </footnote></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0112" lvl="0"><number>&lsqb;0112&rsqb;</number> The missing section between bases 7416 and 7659 was obtained by PCR using the primers 157 (CCA TAA TAT TCA GCA GAA CTA G) (SEQ ID NO:64) and 226 (GCT GAT TCT GTA TAA GGG) (SEQ ID NO:65). The phage DNA of the clone was used as the DNA template. The conditions for the PCR were: 1.) initial denaturation: 94&deg; C., 3 min, 2.) amplification: 1.5 min 94&deg; C., 1 min 56&deg; C. and 1 min 72&deg; C. for 30 cycles. </paragraph>
<paragraph id="P-0113" lvl="0"><number>&lsqb;0113&rsqb;</number> The DNA was sequenced as described in Example 4. Both the strand and the antistrand of the total genome were sequenced. In the case of each site for EcoRI cleavage, PCR employing phage DNA of the clone as the DNA template was used to verify that there was indeed only the one EcoRI cleavage site at each subclone transition point.  
<table-cwu id="TABLE-US-00010">
<number>10</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 5</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>The position of the genes for the virus</entry>
</row>
<row>
<entry>proteins GAG, POL and ENV in the full sequence of MVP-5180</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="35PT" align="left"/>
<colspec colname="1" colwidth="63PT" align="left"/>
<colspec colname="2" colwidth="21PT" align="center"/>
<colspec colname="3" colwidth="98PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>Gene</entry>
<entry>Start<highlight><superscript>1</superscript></highlight></entry>
<entry>Stop<highlight><superscript>1</superscript></highlight></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>GAG</entry>
<entry>&ensp;817</entry>
<entry>2310</entry>
</row>
<row>
<entry></entry>
<entry>POL</entry>
<entry>2073</entry>
<entry>5153</entry>
</row>
<row>
<entry></entry>
<entry>ENV</entry>
<entry>6260</entry>
<entry>8887</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0114" lvl="1"><number>&lsqb;0114&rsqb;</number> 1.) The numbers give the positions of the bases in the full sequence of MVP-5180/91 (SEQ ID NO:56) </paragraph>
<paragraph id="P-0115" lvl="7"><number>&lsqb;0115&rsqb;</number> The full sequence of MVP-5180/91 is presented in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56). </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 10 </heading>
<paragraph id="P-0116" lvl="0"><number>&lsqb;0116&rsqb;</number> Delimitation of the full sequence of MVP-5180/91 (SEQ ID NO:56) from other HIV-1 isolates </paragraph>
<paragraph id="P-0117" lvl="0"><number>&lsqb;0117&rsqb;</number> The databanks Genbank, Release 75 of 2.93, EMBL 33 of 12.92, and Swissprot 24 of 1.93 provided the basis for the following sequence comparisons. Comparisons of homology were carried out using the GCG software (version 7.2, 10.92. from the Genetics Computer Group, Wisconsin). </paragraph>
<paragraph id="P-0118" lvl="0"><number>&lsqb;0118&rsqb;</number> Initially, the sequences of GAG, POL and ENV were compared with the database at the amino acid level using the &ldquo;Wordsearch&rdquo; program. The 50 best homologs were in each case compared with each other using the &ldquo;Pileup&rdquo; program. From this, it clearly emerges that MVP-5180/91 (SEQ ID NO:56) belongs in the HIV-1 genealogical tree but branches off from it at a very early stage, even prior to the chimpanzee virus SIVcpz, and thus represents a novel HIV-1 subfamily. In order to obtain numerical values for the homologies, MVP-5180 (SEQ ID NO:56) was compared with the HIV-1, HIV-2 and SIV sequences which in each case showed the best fit, and in addition with the SIVcpz sequence, using the &ldquo;Gap&rdquo; program.  
<table-cwu id="TABLE-US-00011">
<number>11</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 6</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Homology values for the amino acid</entry>
</row>
<row>
<entry>sequences of GAG, POL and ENV of the MVP-5180/91 isolate</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="9">
<colspec colname="1" colwidth="21PT" align="left"/>
<colspec colname="2" colwidth="21PT" align="left"/>
<colspec colname="3" colwidth="28PT" align="left"/>
<colspec colname="4" colwidth="21PT" align="left"/>
<colspec colname="5" colwidth="28PT" align="left"/>
<colspec colname="6" colwidth="21PT" align="left"/>
<colspec colname="7" colwidth="28PT" align="left"/>
<colspec colname="8" colwidth="21PT" align="left"/>
<colspec colname="9" colwidth="28PT" align="left"/>
<tbody valign="top">
<row>
<entry>GAG</entry>
<entry>SIV-</entry>
<entry>70.2%</entry>
<entry>HIV-</entry>
<entry>69.9%</entry>
<entry>HIV-</entry>
<entry>53.6%</entry>
<entry>SIV-</entry>
<entry>55.1%</entry>
</row>
<row>
<entry></entry>
<entry>cpz</entry>
<entry>83.6%</entry>
<entry>1u<highlight><superscript>2</superscript></highlight></entry>
<entry>81.2%</entry>
<entry>2d<highlight><superscript>3</superscript></highlight></entry>
<entry>71.3%</entry>
<entry>1a<highlight><superscript>4</superscript></highlight></entry>
<entry>71.3%</entry>
</row>
<row>
<entry>POL</entry>
<entry>SIV-</entry>
<entry>78.0%</entry>
<entry>HIV-</entry>
<entry>76.1%</entry>
<entry>HIV-</entry>
<entry>57.2%</entry>
<entry>SIV-</entry>
<entry>57.7%</entry>
</row>
<row>
<entry></entry>
<entry>cpz</entry>
<entry>88.0%</entry>
<entry>1u<highlight><superscript>2</superscript></highlight></entry>
<entry>86.8%</entry>
<entry>2d<highlight><superscript>3</superscript></highlight></entry>
<entry>71.9%</entry>
<entry>gb<highlight><superscript>5</superscript></highlight></entry>
<entry>74.6%</entry>
</row>
<row>
<entry>ENV</entry>
<entry>SIV-</entry>
<entry>53.4%</entry>
<entry>HIV-</entry>
<entry>50.9%</entry>
<entry>HIV-</entry>
<entry>34.4%</entry>
<entry>SIV-</entry>
<entry>34.4%</entry>
</row>
<row>
<entry></entry>
<entry>cpz</entry>
<entry>67.1%</entry>
<entry>1h<highlight><superscript>1</superscript></highlight></entry>
<entry>67.2%</entry>
<entry>2d<highlight><superscript>3</superscript></highlight></entry>
<entry>58.7%</entry>
<entry>at<highlight><superscript>6</superscript></highlight></entry>
<entry>57.8%</entry>
</row>
<row><entry namest="1" nameend="9" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00002"><highlight><superscript>1</superscript></highlight>h&equals; hz321/Zaire, </footnote></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00003"><highlight><superscript>2</superscript></highlight>u&equals; u455/Uganda, </footnote></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00004"><highlight><superscript>3</superscript></highlight>d&equals; jrcst, </footnote></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00005"><highlight><superscript>4</superscript></highlight>a&equals; agm155, </footnote></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00006"><highlight><superscript>5</superscript></highlight>gb&equals; gb1, </footnote></entry>
</row>
<row>
<entry namest="1" nameend="9" align="left"><footnote id="FOO-00007"><highlight><superscript>6</superscript></highlight>at&equals; agm </footnote></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0119" lvl="0"><number>&lsqb;0119&rsqb;</number> The upper numerical value expresses the identity and the lower value the similarity of the two sequences. </paragraph>
<paragraph id="P-0120" lvl="0"><number>&lsqb;0120&rsqb;</number> In addition to this, the database was searched at the nucleotide level using &ldquo;Wordsearch&rdquo; and &ldquo;Gap&rdquo;. The homology values for the best matches in each- case are compiled in Table 7.  
<table-cwu id="TABLE-US-00012">
<number>12</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 7</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Homology values for the nucleotide</entry>
</row>
<row>
<entry>sequence of MVP-5180/91</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="42PT" align="left"/>
<colspec colname="1" colwidth="91PT" align="left"/>
<colspec colname="2" colwidth="84PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>HIV1</entry>
<entry>HIV2</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="28PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="left"/>
<colspec colname="3" colwidth="49PT" align="center"/>
<colspec colname="4" colwidth="42PT" align="left"/>
<colspec colname="5" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>gag</entry>
<entry>HIVelicg</entry>
<entry>70.24%&ensp;</entry>
<entry>HIV2bihz</entry>
<entry>60.0%</entry>
</row>
<row>
<entry></entry>
<entry>pol</entry>
<entry>HIVmal</entry>
<entry>75.0%</entry>
<entry>HIV2cam2</entry>
<entry>62.9%</entry>
</row>
<row>
<entry></entry>
<entry>env</entry>
<entry>HTVsimi84</entry>
<entry>59.7%</entry>
<entry>HIV2gha</entry>
<entry>49.8&ensp;</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 11 </heading>
<paragraph id="P-0121" lvl="0"><number>&lsqb;0121&rsqb;</number> Description of the PCR amplification, cloning and sequencing of the gag gene of the HIV 5180 isolate. </paragraph>
<paragraph id="P-0122" lvl="0"><number>&lsqb;0122&rsqb;</number> In order to depict the spontaneous mutations arising during the course of virus multiplication, a part of the viral genome was cloned using the PCR technique and the DNA sequence thus obtained was compared with the sequence according to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NQ:56). </paragraph>
<paragraph id="P-0123" lvl="0"><number>&lsqb;0123&rsqb;</number> The gag sequence was cloned in an overlapping manner from the LTR (long terminal repeat, LTRl primer) of the left end of the MVP-5180 genome through into the pol gene (polymerase gene, pol3.5i primer). The cloning strategy is depicted schematically in <cross-reference target="DRAWINGS">FIG. 5</cross-reference>. </paragraph>
<paragraph id="P-0124" lvl="0"><number>&lsqb;0124&rsqb;</number> The PCR reactions were carried out using the DNA primers given below, whose sequences were derived from the HIV-1 consensus sequence. The sequencings were carried out using the dideoxy chain termination method. </paragraph>
<paragraph id="P-0125" lvl="0"><number>&lsqb;0125&rsqb;</number> The sequence encoding the MVP-5180 gag gene extends from nucleotide 817 (A of the ATG start codon) to nucleotide 2300 (A of the last codon).  
<table-cwu id="TABLE-US-00013">
<number>13</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="105PT" align="left"/>
<colspec colname="2" colwidth="175PT" align="left"/>
<colspec colname="3" colwidth="-287PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row>
<entry>LTR1 (SEQ ID NO:47):</entry>
<entry>5&prime;-CTA GCA GTG GCG CCC GAA CAG G-3&prime;</entry>
<entry></entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag3.5 (SEQ ID NO:48):</entry>
<entry>5&prime;-AAT GAG GAA GCU GCA GAU TGG GA-3&prime;</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;&emsp;&emsp;&emsp;(U&equals;A/T)</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag 3.51 (SEQ ID NO:49):</entry>
<entry>5&prime;-TCC CAU TCT GCU GCT TCC TCA TT-3&prime;</entry>
</row>
<row>
<entry></entry>
<entry>&emsp;&emsp;&emsp;&emsp;&emsp;(U&equals;A/T)</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag5 (SEQ ID NO:5O):</entry>
<entry>5&prime;-CCA AGG GGA AGT GAC ATA GCA GGA AC-3&prime;</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag959 (SEQ ID NO:51):</entry>
<entry>5&prime;-CGT TGT TCA GAA TTC AAA CCC-3&prime;</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>gag11i (SEQ ID NO:52):</entry>
<entry>5&prime;-TCC CTA AAA AAT TAG CCT GTC-3&prime;</entry>
</row>
<row>
<entry> </entry>
</row>
<row>
<entry>po13.5i (SEQ ID NO:53):</entry>
<entry>5&prime;-AAA CCT CCA ATT CCC CCT A-3&prime;</entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0126" lvl="0"><number>&lsqb;0126&rsqb;</number> The DNA sequence obtained using the PCR technique was compared with the DNA sequence presented in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56). A comparison of the two DNA sequences is presented in <cross-reference target="DRAWINGS">FIG. 6</cross-reference>. <cross-reference target="DRAWINGS">FIG. 6</cross-reference> includes SEQ ID NO:57, which corresponds to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56) and SEQ ID NO:58, which corresponds to the DNA sequence obtained using the PCR technique. This showed that about 2% of the nucleotides differ from each other, although the virus is the same in the two cases. In <cross-reference target="DRAWINGS">FIG. 6</cross-reference>, the upper line in each case represents the DNA sequence which is presented in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56) and the lower line represents the DNA sequence obtained using the PCR technique. </paragraph>
<paragraph id="P-0127" lvl="0"><number>&lsqb;0127&rsqb;</number> In addition, the amino acid sequence of the gag protein, elucidated using the PCR technique, was compared with the amino acid sequence of the corresponding protein deduced from <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:59). This showed an amino acid difference of about 2.2%. The comparison is presented in <cross-reference target="DRAWINGS">FIG. 7</cross-reference>, the lower line in each case representing the amino acid sequence which was deduced from the sequence obtained using the PCR technique. <cross-reference target="DRAWINGS">FIG. 7</cross-reference> includes amino acid SEQ ID NO:59, which was elucidated in accordance with <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56), and the amino acid sequence (SEQ ID NO:60) derived using the PCR technique. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 12 </heading>
<paragraph id="P-0128" lvl="0"><number>&lsqb;0128&rsqb;</number> The sequence of the virus MVP-5180 (SEQ ID NO:56) according to the invention was compared with the consensus sequences of HIV-1 and HIV-2, and with the sequence of ANT-70 (WO 89/12094), insofar as this was known. </paragraph>
<paragraph id="P-0129" lvl="0"><number>&lsqb;0129&rsqb;</number> In this connection, the following results were obtained:  
<table-cwu id="TABLE-US-00014">
<number>14</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="49PT" align="left"/>
<colspec colname="2" colwidth="49PT" align="center"/>
<colspec colname="3" colwidth="56PT" align="center"/>
<colspec colname="4" colwidth="63PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="4" align="center">TABLE 8</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Deviating</entry>
<entry>Number of the</entry>
<entry>% homology</entry>
</row>
<row>
<entry>Gene locus</entry>
<entry>nucleotides</entry>
<entry>nucleotides</entry>
<entry>(approximated)</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="49PT" align="left"/>
<colspec colname="2" colwidth="49PT" align="center"/>
<colspec colname="3" colwidth="56PT" align="center"/>
<colspec colname="4" colwidth="35PT" align="left"/>
<colspec colname="5" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry>LTR</entry>
<entry>207</entry>
<entry>&ensp;630</entry>
<entry>HIV-1</entry>
<entry>67%</entry>
</row>
<row>
<entry></entry>
<entry>308</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>51%</entry>
</row>
<row>
<entry></entry>
<entry>115</entry>
<entry></entry>
<entry>ANT 70</entry>
<entry>82%</entry>
</row>
<row>
<entry>GAG</entry>
<entry>448</entry>
<entry>1501</entry>
<entry>HIV-1</entry>
<entry>70%</entry>
</row>
<row>
<entry></entry>
<entry>570</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>62%</entry>
</row>
<row>
<entry>POL</entry>
<entry>763</entry>
<entry>3010</entry>
<entry>HIV-1</entry>
<entry>74%</entry>
</row>
<row>
<entry></entry>
<entry>1011&ensp;</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>66%</entry>
</row>
<row>
<entry>VIF</entry>
<entry>183</entry>
<entry>&ensp;578</entry>
<entry>HIV-1</entry>
<entry>68%</entry>
</row>
<row>
<entry></entry>
<entry>338</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>42%</entry>
</row>
<row>
<entry>ENV</entry>
<entry>1196&ensp;</entry>
<entry>2534</entry>
<entry>HIV-1</entry>
<entry>53%</entry>
</row>
<row>
<entry></entry>
<entry>1289&ensp;</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>49%</entry>
</row>
<row>
<entry>NEF</entry>
<entry>285</entry>
<entry>&ensp;621</entry>
<entry>HIV-1</entry>
<entry>54%</entry>
</row>
<row>
<entry></entry>
<entry>342</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>45%</entry>
</row>
<row>
<entry>total</entry>
<entry>3082&ensp;</entry>
<entry>8874</entry>
<entry>HIV-1</entry>
<entry>65%</entry>
</row>
<row>
<entry></entry>
<entry>3858&ensp;</entry>
<entry></entry>
<entry>HIV-2</entry>
<entry>56%</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0130" lvl="0"><number>&lsqb;0130&rsqb;</number> In the above table, &ldquo;HIV-1&rdquo;, denotes consensus sequences of HIV-1 viruses; &ldquo;HIV-2&rdquo; denotes consensus sequences of HIV-2 viruses; ANT-70 denotes the partial sequence of a virus designated HIV-3 and disclosed in WO 89/12094. </paragraph>
<paragraph id="P-0131" lvl="0"><number>&lsqb;0131&rsqb;</number> The present invention therefore relates to viruses, DNA sequences and amino acid sequences, and constituent sequences thereof, which possess such a degree of homology with the sequence presented in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56), based on the gene loci, that at most the fractions given in Table 9, expressed in % values, are different.  
<table-cwu id="TABLE-US-00015">
<number>15</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 9</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Homology based on gene loci, expressed as</entry>
</row>
<row>
<entry>maximum differences</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="42PT" align="left"/>
<colspec colname="2" colwidth="63PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="56PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>Particularly</entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>Preferred</entry>
<entry>preferred</entry>
</row>
<row>
<entry></entry>
<entry>Gene locus</entry>
<entry>Differences</entry>
<entry>differences</entry>
<entry>differences</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>LTR</entry>
<entry>17%</entry>
<entry>15%</entry>
<entry>10%</entry>
</row>
<row>
<entry></entry>
<entry>GAG</entry>
<entry>29%</entry>
<entry>28%</entry>
<entry>14%</entry>
</row>
<row>
<entry></entry>
<entry>POL</entry>
<entry>25%</entry>
<entry>24%</entry>
<entry>12%</entry>
</row>
<row>
<entry></entry>
<entry>VIF</entry>
<entry>31%</entry>
<entry>30%</entry>
<entry>15%</entry>
</row>
<row>
<entry></entry>
<entry>ENV</entry>
<entry>46%</entry>
<entry>45%</entry>
<entry>22%</entry>
</row>
<row>
<entry></entry>
<entry>NEF</entry>
<entry>16%</entry>
<entry>12%</entry>
<entry>10%</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0132" lvl="0"><number>&lsqb;0132&rsqb;</number> The homology values in % given in Table 9 mean that, when comparing the sequence according to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> (SEQ ID NO:56) with a sequence of another virus, at most a fraction of the sequence corresponding to the abovementioned percentage values may be different. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE13: V3 LOOP </heading>
<paragraph id="P-0133" lvl="0"><number>&lsqb;0133&rsqb;</number> This loop is the main neutralizing region in HIV and the immunological specificities of the region are documented in summary form in <cross-reference target="DRAWINGS">FIG. 8</cross-reference>. This is a copy from a work by Peter Nara (1990) from AIDS. The amino acid sequence of the V3 loop is shown diagrammatically and is compared with the IIIB virus, now LAI, and the first HIV-2 isolate (ROD). Individual amino acids are conserved at the cystine bridge. Whereas the crown of HIV-1 is GPGR or GPGQ and that of HIV-2 is GHVF, the crown of MVP-5180/91 (SEQ ID NO:56) is formed from the amino acids GPMR. The motif with methionine has not previously been described and, emphasizes the individuality of MVP-5180/91 (SEQ ID NO:56). </paragraph>
<paragraph id="P-0134" lvl="0"><number>&lsqb;0134&rsqb;</number> After having determined the nucleotide sequence of the virus the V3-loop-region was amplified using the PCR-technique by using suitable primers. Some mutations have been observed, especially a change of the methionine codon (ATG) to the leucine codon (CTG). </paragraph>
<paragraph id="P-0135" lvl="0"><number>&lsqb;0135&rsqb;</number> In the following the amino acid sequence derived from the cloned nucleic acid is compared with a sequence obtained after amplification with the help of PCR technology.  
<table-cwu id="TABLE-US-00016">
<number>16</number>
<table frame="none" colsep="0" rowsep="0" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="21PT" align="left"/>
<colspec colname="1" colwidth="196PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>MvP 5180 (cloned) (SEQ ID NO:54):</entry>
</row>
<row>
<entry></entry>
<entry>CIREGIAEVQDIYTGPMRWRSMTLKRSNNTSPRSRVAYC</entry>
</row>
<row>
<entry></entry>
<entry> </entry>
</row>
<row>
<entry></entry>
<entry>MvP 5180 (PCT technique) (SEQ ID NO:55):</entry>
</row>
<row>
<entry></entry>
<entry>CIREGIAEVQDLHTGPLRWRSMTLKKSSNSHTQPRSKVAYC</entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 14 </heading>
<paragraph id="P-0136" lvl="0"><number>&lsqb;0136&rsqb;</number> In order to demonstrate that even those sera which cannot be identified in a normal HIV-1&plus;2 screening test can be proved to be HIV-1-positive with the aid of the virus MVP-5180 (SEQ ID NO:56) according to the invention, or antigens derived therefrom, various sera from patients from the Cameroons were examined in the EIA test. </paragraph>
<paragraph id="P-0137" lvl="0"><number>&lsqb;0137&rsqb;</number> 156 anti-HIV-1-positive sera were examined in a study carried out in the Cameroons. Substantial, diagnostically relevant differences were observed in two of these sera. The extinctions which were measured are given in Table 10 below. CAM-A and CAM-B denote the sera of different patients.  
<table-cwu id="TABLE-US-00017">
<number>17</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="56PT" align="left"/>
<colspec colname="2" colwidth="56PT" align="center"/>
<colspec colname="3" colwidth="91PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center">TABLE 10</entry>
</row>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Patient sera</entry>
<entry>MVP-5180-EIA</entry>
<entry>HIV-1 &plus; HIV-2 EIA</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>CAM-A</entry>
<entry>2.886</entry>
<entry>1.623</entry>
</row>
<row>
<entry></entry>
<entry>CAM-B</entry>
<entry>1.102</entry>
<entry>0.386</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="left"><footnote id="FOO-00008">The cutoff for both tests was 0.300. </footnote></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0138" lvl="0"><number>&lsqb;0138&rsqb;</number> In a further study on 47 anti-HIV-1-positive sera from the Cameroons, two sera were of particular note. One of these (93-1000) derives from a patient showing relatively few symptoms and the other (93-1001) from a patient suffering from AIDS. The extinction values for the two EIA tests are compared in Table 11 below:  
<table-cwu id="TABLE-US-00018">
<number>18</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="70PT" align="center"/>
<colspec colname="2" colwidth="56PT" align="center"/>
<colspec colname="3" colwidth="91PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="3" align="center">TABLE 11</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Patient sera</entry>
<entry>MVP-5180-EIA</entry>
<entry>HIV-1 &plus; HIV-2 EIA</entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="70PT" align="center"/>
<colspec colname="2" colwidth="56PT" align="char" char="."/>
<colspec colname="3" colwidth="91PT" align="center"/>
<tbody valign="top">
<row>
<entry>93-1000</entry>
<entry>&gt;2.5</entry>
<entry>1.495</entry>
</row>
<row>
<entry>93-1001</entry>
<entry>0.692</entry>
<entry>0.314</entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0139" lvl="0"><number>&lsqb;0139&rsqb;</number> The cutoff was 0.3 in this case as well. The extinction values for patient 93-1001 demonstrate that the normal HIV-1&plus;HIV-2 EIA can fail whereas clear detection is possible the antigen according to the invention is employed. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<sequence-cwu id="SEQLST-1">
<number>1</number>
<sequence-list-new-rules>
<s100>
<s160>67 </s160>
</s100>
<s200>
<s210>1 </s210>
<s211>18 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 1 
ctactagtac ccttcagg                                                   18 
</s400>
<s200>
<s210>2 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 2 
cggtctacat agtctctaaa g                                               21 
</s400>
<s200>
<s210>3 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 3 
ccacctatcc cagtaggaga a                                               21 
</s400>
<s200>
<s210>4 </s210>
<s211>30 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 4 
cctttggtcc ttgtcttatg tccagaatgc                                      30 
</s400>
<s200>
<s210>5 </s210>
<s211>25 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 5 
tgggaagttc aattaggaat accac                                           25 
</s400>
<s200>
<s210>6 </s210>
<s211>26 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 6 
cctacataga aatcatccat gtattg                                          26 
</s400>
<s200>
<s210>7 </s210>
<s211>19 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 7 
tggatgtggg tgatgcata                                                  19 
</s400>
<s200>
<s210>8 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 8 
agcacattgt actgatatct a                                               21 
</s400>
<s200>
<s210>9 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 9 
agtgggggga catcaagcag cc                                              22 
</s400>
<s200>
<s210>10 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 10 
tgctatgtca cttccccttg gt                                              22 
</s400>
<s200>
<s210>11 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 11 
ccatgcaaat gttaaaagag ac                                              22 
</s400>
<s200>
<s210>12 </s210>
<s211>19 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 12 
ggcctggtgc aataggccc                                                  19 
</s400>
<s200>
<s210>13 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 13 
gtgcttccac agggatggaa                                                 20 
</s400>
<s200>
<s210>14 </s210>
<s211>18 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 14 
atcatccatg tattgata                                                   18 
</s400>
<s200>
<s210>15 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 15 
aatggagcca gtagatccta                                                 20 
</s400>
<s200>
<s210>16 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 16 
tgtctccgct tcttcctgcc                                                 20 
</s400>
<s200>
<s210>17 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 17 
gagccctgga agcatccagg                                                 20 
</s400>
<s200>
<s210>18 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 18 
ggagatgcct aaggcttttg                                                 20 
</s400>
<s200>
<s210>19 </s210>
<s211>17 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 19 
tgttccttgg gttcttg                                                    17 
</s400>
<s200>
<s210>20 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 20 
gagttttcca gagcaacccc                                                 20 
</s400>
<s200>
<s210>21 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 21 
agcagcagga agcactatgg                                                 20 
</s400>
<s200>
<s210>22 </s210>
<s211>24 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 22 
gccccagact gtgagttgca acag                                            24 
</s400>
<s200>
<s210>23 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 23 
gcacagtaca atgtacacat gg                                              22 
</s400>
<s200>
<s210>24 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 24 
cagtagaaaa attcccctcc ac                                              22 
</s400>
<s200>
<s210>25 </s210>
<s211>31 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 25 
tcaggatcca tgggcagtct agcagaagaa g                                    31 
</s400>
<s200>
<s210>26 </s210>
<s211>42 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 26 
atgctcgaga actgcagcat cgattctggg tcccctcctg ag                        42 
</s400>
<s200>
<s210>27 </s210>
<s211>40 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 27 
cgagaactgc agcatcgatg ctgctcccaa gaacccaagg                           40 
</s400>
<s200>
<s210>28 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 28 
ggagctgctt gatgccccag a                                               21 
</s400>
<s200>
<s210>29 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 29 
tgatgacagc atgtcaggga gt                                              22 
</s400>
<s200>
<s210>30 </s210>
<s211>25 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 30 
gctgacattt atcacagctg gctac                                           25 
</s400>
<s200>
<s210>31 </s210>
<s211>27 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 31 
tatcacctag aactttaaat gcatggg                                         27 
</s400>
<s200>
<s210>32 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 32 
agtccctgac atgctgtcat ca                                              22 
</s400>
<s200>
<s210>33 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 33 
gtggagggga atttttctac tg                                              22 
</s400>
<s200>
<s210>34 </s210>
<s211>24 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 34 
cctgctgctc ccaagaaccc aagg                                            24 
</s400>
<s200>
<s210>35 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 35 
agcagcagga agcactatgg                                                 20 
</s400>
<s200>
<s210>36 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 36 
gagttttcca gagcaacccc                                                 20 
</s400>
<s200>
<s210>37 </s210>
<s211>195 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
<s220>
<s221>CDS </s221>
<s222>(3)..(194) </s222>
</s220>
</s200>
<s400> 37 
gc gca gcg gca aca gcg ctg acg gta cgg acc cac agt gta ctg aag        47 
   Ala Ala Ala Thr Ala Leu Thr Val Arg Thr His Ser Val Leu Lys 
     1               5                  10                  15 
ggt ata gtg caa cag cag gac aac ctg ctg aga gcg ata cag gcc cag       95 
Gly Ile Val Gln Gln Gln Asp Asn Leu Leu Arg Ala Ile Gln Ala Gln 
                 20                  25                  30 
caa cac ttg ctg agg tta tct gta tgg ggt att aga caa ctc cga gct      143 
Gln His Leu Leu Arg Leu Ser Val Trp Gly Ile Arg Gln Leu Arg Ala 
             35                  40                  45 
cgc ctg caa gcc tta gaa acc ctt ata cag aat cag caa cgc cta aac      191 
Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Arg Leu Asn 
         50                  55                  60 
cta t                                                                195 
Leu 
</s400>
<s200>
<s210>38 </s210>
<s211>195 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 38 
ataggtttag gcgttgctga ttctgtataa gggtttctaa ggcttgcagg cgagctcgga     60 
gttgtctaat accccataca gataacctca gcaagtgttg ctgggcctgt atcgctctca    120 
gcaggttgtc ctgctgttgc actataccct tcagtacact gtgggtccgt accgtcagcg    180 
tgttgccgc tgcgc                                                      195 
</s400>
<s200>
<s210>39 </s210>
<s211>64 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 39 
Ala Ala Ala Thr Ala Leu Thr Val Arg Thr His Ser Val Leu Lys Gly 
  1               5                  10                  15 
Ile Val Gln Gln Gln Asp Asn Leu Leu Arg Ala Ile Gln Ala Gln Gln 
             20                  25                  30 
His Leu Leu Arg Leu Ser Val Trp Gly Ile Arg Gln Leu Arg Ala Arg 
         35                  40                  45 
Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Arg Leu Asn Leu 
     50                  55                  60 
</s400>
<s200>
<s210>40 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 40 
cagaatcagc aacgcctaaa cc                                              22 
</s400>
<s200>
<s210>41 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 41 
gccctgtctt attcttctag g                                               21 
</s400>
<s200>
<s210>42 </s210>
<s211>20 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 42 
gcctgcaagc cttagaaacc                                                 20 
</s400>
<s200>
<s210>43 </s210>
<s211>23 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 43 
gcactatacc cttcagtaca ctg                                             23 
</s400>
<s200>
<s210>44 </s210>
<s211>1057 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
<s220>
<s221>CDS </s221>
<s222>(3)..(1055) </s222>
</s220>
</s200>
<s400> 44 
aa atg tca aga cca ata ata aac att cac acc cct cac agg gaa aaa        47 
   Met Ser Arg Pro Ile Ile Asn Ile His Thr Pro His Arg Glu Lys 
     1               5                  10                  15 
aga cga gta gga ttg gga atg cta ttc ttg ggg gtg cta agt gca gca       95 
Arg Arg Val Gly Leu Gly Met Leu Phe Leu Gly Val Leu Ser Ala Ala 
                 20                  25                  30 
ggt agc act atg ggc gca gcg gca aca gcg ctg acg gta cgg acc cac      143 
Gly Ser Thr Met Gly Ala Ala Ala Thr Ala Leu Thr Val Arg Thr His 
             35                  40                  45 
agt gta ctg aag ggt ata gtg caa cag cag gac aac ctg ctg aga gcg      191 
Ser Val Leu Lys Gly Ile Val Gln Gln Gln Asp Asn Leu Leu Arg Ala 
         50                  55                  60 
ata cag gcc cag caa cac ttg ctg agg tta tct gta tgg ggt att aga      239 
Ile Gln Ala Gln Gln His Leu Leu Arg Leu Ser Val Trp Gly Ile Arg 
     65                  70                  75 
caa ctc cga gct cgc ctg caa gcc tta gaa acc ctt ata cag aat cag      287 
Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln 
 80                  85                  90                  95 
caa cgc cta aac cta tgg ggc tgt aaa gga aaa cta atc tgt tac aca      335 
Gln Arg Leu Asn Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr 
                100                 105                 110 
tca gta aaa tgg aac aca tca tgg tca gga gga tat aat gat gac agt      383 
Ser Val Lys Trp Asn Thr Ser Trp Ser Gly Gly Tyr Asn Asp Asp Ser 
            115                 120                 125 
att tgg gac aac ctt aca tgg cag caa tgg gac caa cac ata aac aat      431 
Ile Trp Asp Asn Leu Thr Trp Gln Gln Trp Asp Gln His Ile Asn Asn 
        130                 135                 140 
gta agc tcc att ata tat gat gaa ata caa gca gca caa gac caa cag      479 
Val Ser Ser Ile Ile Tyr Asp Glu Ile Gln Ala Ala Gln Asp Gln Gln 
    145                 150                 155 
gaa aag aat gta aaa gca ttg ttg gag cta gat gaa tgg gcc tct ctt      527 
Glu Lys Asn Val Lys Ala Leu Leu Glu Leu Asp Glu Trp Ala Ser Leu 
160                 165                 170                 175 
tgg aat tgg ttt gac ata act aaa tgg ttg tgg tat ata aaa ata gct      575 
Trp Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr Ile Lys Ile Ala 
                180                 185                 190 
ata atc ata gtg gga gca cta ata ggt ata aga gtt atc atg ata gta      623 
Ile Ile Ile Val Gly Ala Leu Ile Gly Ile Arg Val Ile Met Ile Val 
            195                 200                 205 
ctt aat cta gtg aag aac att agg cag gga tat caa ccc ctc tcg ttg      671 
Leu Asn Leu Val Lys Asn Ile Arg Gln Gly Tyr Gln Pro Leu Ser Leu 
        210                 215                 220 
cag atc cct gtc cca cac cgg cag gaa gca gaa acg cca gga aga aca      719 
Gln Ile Pro Val Pro His Arg Gln Glu Ala Glu Thr Pro Gly Arg Thr 
    225                 230                 235 
gga gaa gaa ggt gga gaa gga gac agg ccc aag tgg aca gcc ttg cca      767 
Gly Glu Glu Gly Gly Glu Gly Asp Arg Pro Lys Trp Thr Ala Leu Pro 
240                 245                 250                 255 
cca gga ttc ttg caa cag ttg tac acg gat ctc agg aca ata atc ttg      815 
Pro Gly Phe Leu Gln Gln Leu Tyr Thr Asp Leu Arg Thr Ile Ile Leu 
                260                 265                 270 
tgg act tac cac ctc ttg agc aac tta ata tca ggg atc cgg agg ctg      863 
Trp Thr Tyr His Leu Leu Ser Asn Leu Ile Ser Gly Ile Arg Arg Leu 
            275                 280                 285 
atc gac tac ctg gga ctg gga ctg tgg atc ctg gga caa aag aca att      911 
Ile Asp Tyr Leu Gly Leu Gly Leu Trp Ile Leu Gly Gln Lys Thr Ile 
        290                 295                 300 
gaa gct tgt aga ctt tgt gga gct gta atg caa tat tgg cta caa gaa      959 
Glu Ala Cys Arg Leu Cys Gly Ala Val Met Gln Tyr Trp Leu Gln Glu 
    305                 310                 315 
ttg aaa aat agt gct aca aac ctg ctt gat act att gca gtg tca gtt     1007 
Leu Lys Asn Ser Ala Thr Asn Leu Leu Asp Thr Ile Ala Val Ser Val 
320                 325                 330                 335 
gcc aat tgg act gac ggc atc atc tta ggt cta caa aga ata gga caa     1055 
Ala Asn Trp Thr Asp Gly Ile Ile Leu Gly Leu Gln Arg Ile Gly Gln 
                340                 345                 350 
gg                                                                  1057 
</s400>
<s200>
<s210>45 </s210>
<s211>1057 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 45 
ccttgtccta ttctttgtag acctaagatg atgccgtcag tccaattggc aactgcaact     60 
gcaatagtat caagcaggtt tgtagcacta tttttcaatt cttgtagcca atattgcatt    120 
acagctccac aaagtctaca agcttcaatt gtcttttgtc ccaggatcca cagtcccagt    180 
cccaggtagt cgatcagcct ccggatccct gatattaagt tgctcaagag gtggtaagtc    240 
cacaagatta ttgtcctgag atccgtgtac aactgttgca agaatcctgg tggcaaggct    300 
gtccacttgg gcctgtctcc ttctccacct tcttctcctg ttcttcctgg cgtttctgct    360 
tcctgccggt gtgggacagg gatctgcaac gagaggggtt gatatccctg cctaatgttc    420 
ttcactagat taagtactat catgataact cttataccta ttagtgctcc cactatgatt    480 
atagctattt ttatatacca caaccattta gttatgtcaa accaattcca aagagaggcc    540 
cattcatcta gctccaacaa tgcttttaca ttcttttcct gttggtcttg tgctgcttgt    600 
atttcatcat atataatgga gcttacattg tttatgtgtt ggtcccattg ctgccatgta    660 
aggttgtccc aaatactgtc atcattatat cctcctgacc atgatgtgtt ccattttact    720 
gatgtgtaac agattagttt tcctttacag ccccataggt ttaggcgttg ctgattctgt    780 
ataagggttt ctaaggcttg caggcgagct cggagttgtc taatacccca tacagataac    840 
ctcagcaagt gttgctgggc ctgtatcgct ctcagcaggt tgtcctgctg ttgcactata    900 
cccttcagta cactgtgggt ccgtaccgtc agcgctgttg ccgctgcgcc catagtgcta    960 
cctgctgcac ttagcacccc caagaatagc attcccaatc ctactgctct tttttccctg   1020 
tgaggggtgt gaatgtttat tattggtctt gacattt                            1057 
</s400>
<s200>
<s210>46 </s210>
<s211>351 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 46 
Met Ser Arg Pro Ile Ile Asn Ile His Thr Pro His Arg Glu Lys Arg 
  1               5                  10                  15 
Arg Val Gly Leu Gly Met Leu Phe Leu Gly Val Leu Ser Ala Ala Gly 
             20                  25                  30 
Ser Thr Met Gly Ala Ala Ala Thr Ala Leu Thr Val Arg Thr His Ser 
         35                  40                  45 
Val Leu Lys Gly Ile Val Gln Gln Gln Asp Asn Leu Leu Arg Ala Ile 
     50                  55                  60 
Gln Ala Gln Gln His Leu Leu Arg Leu Ser Val Trp Gly Ile Arg Gln 
 65                  70                  75                  80 
Leu Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln 
                 85                  90                  95 
Arg Leu Asn Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr Ser 
            100                 105                 110 
Val Lys Trp Asn Thr Ser Trp Ser Gly Gly Tyr Asn Asp Asp Ser Ile 
        115                 120                 125 
Trp Asp Asn Leu Thr Trp Gln Gln Trp Asp Gln His Ile Asn Asn Val 
    130                 135                 140 
Ser Ser Ile Ile Tyr Asp Glu Ile Gln Ala Ala Gln Asp Gln Gln Glu 
145                 150                 155                 160 
Lys Asn Val Lys Ala Leu Leu Glu Leu Asp Glu Trp Ala Ser Leu Trp 
                165                 170                 175 
Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr Ile Lys Ile Ala Ile 
            180                 185                 190 
Ile Ile Val Gly Ala Leu Ile Gly Ile Arg Val Ile Met Ile Val Leu 
        195                 200                 205 
Asn Leu Val Lys Asn Ile Arg Gln Gly Tyr Gln Pro Leu Ser Leu Gln 
    210                 215                 220 
Ile Pro Val Pro His Arg Gln Glu Ala Glu Thr Pro Gly Arg Thr Gly 
225                 230                 235                 240 
Glu Glu Gly Gly Glu Gly Asp Arg Pro Lys Trp Thr Ala Leu Pro Pro 
                245                 250                 255 
Gly Phe Leu Gln Gln Leu Tyr Thr Asp Leu Arg Thr Ile Ile Leu Trp 
            260                 265                 270 
Thr Tyr His Leu Leu Ser Asn Leu Ile Ser Gly Ile Arg Arg Leu Ile 
        275                 280                 285 
Asp Tyr Leu Gly Leu Gly Leu Trp Ile Leu Gly Gln Lys Thr Ile Glu 
    290                 295                 300 
Ala Cys Arg Leu Cys Gly Ala Val Met Gln Tyr Trp Leu Gln Glu Leu 
305                 310                 315                 320 
Lys Asn Ser Ala Thr Asn Leu Leu Asp Thr Ile Ala Val Ser Val Ala 
                325                 330                 335 
Asn Trp Thr Asp Gly Ile Ile Leu Gly Leu Gln Arg Ile Gly Gln 
            340                 345                 350 
</s400>
<s200>
<s210>47 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 47 
ctagcagtgg cgcccgaaca gg                                              22 
</s400>
<s200>
<s210>48 </s210>
<s211>23 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 48 
aatgaggaag cwgcagawtg gga                                             23 
</s400>
<s200>
<s210>49 </s210>
<s211>23 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 49 
tcccawtctg cwgcttcctc att                                             23 
</s400>
<s200>
<s210>50 </s210>
<s211>26 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 50 
ccaaggggaa gtgacatagc aggaac                                          26 
</s400>
<s200>
<s210>51 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 51 
cgttgttcag aattcaaacc c                                               21 
</s400>
<s200>
<s210>52 </s210>
<s211>21 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 52 
tccctaaaaa attagcctgt c                                               21 
</s400>
<s200>
<s210>53 </s210>
<s211>19 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 53 
aaacctccaa ttcccccta                                                  19 
</s400>
<s200>
<s210>54 </s210>
<s211>39 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 54 
Cys Ile Arg Glu Gly Ile Ala Glu Val Gln Asp Ile Tyr Thr Gly Pro 
  1               5                  10                  15 
Met Arg Trp Arg Ser Met Thr Leu Lys Arg Ser Asn Asn Thr Ser Pro 
             20                  25                  30 
Arg Ser Arg Val Ala Tyr Cys 
         35 
</s400>
<s200>
<s210>55 </s210>
<s211>41 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 55 
Cys Ile Arg Glu Gly Ile Ala Glu Val Gln Asp Leu His Thr Gly Pro 
  1               5                  10                  15 
Leu Arg Trp Arg Ser Met Thr Leu Lys Lys Ser Ser Asn Ser His Thr 
             20                  25                  30 
Gln Pro Arg Ser Lys Val Ala Tyr Cys 
         35                  40 
</s400>
<s200>
<s210>56 </s210>
<s211>9793 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 56 
ctggatgggt taatttactc ccataagaga gcagaaatcc tggatctctg gatatatcac     60 
actcagggat tcttccctga ttggcagtgt tacacaccgg gaccaggacc tagattccca    120 
ctgacatttg gatggttgtt taaactggta ccagtgtcag cagaagaggc agagagactg    180 
ggtaatacaa atgaagatgc tagtcttcta catccagctt gtaatcatgg agctgaggat    240 
gcacacgggg agatactaaa atggcagttt gatagatcat taggcttaac acatatagcc    300 
ctgcaaaagc acccagagct cttccccaag taactgacac tgcgggactt tccagactgc    360 
tgacactgcg gggactttcc agcgtgggag ggataagggg cggttcgggg agtggctaac    420 
cctcagatgc tgcatataag cagctgcttt ccgcttgtac cgggtcttag ttagaggacc    480 
aggtctgagc ccgggagctc cctggcctct agctgaaccc gctgcttaac gctcaataaa    540 
gcttgccttg agtgagaagc agtgtgtgct catctgttca accctggtgt ctagagatcc    600 
ctcagatcac ttagactgaa gcagaaaatc tctagcagtg gcgcccgaac agggacgcga    660 
aagtgaaagt ggaaccaggg aagaaaacct ccgacgcaac gggctcggct tagcggagtg    720 
cacctgctaa gaggcgagag gaactcacaa gagggtgagt aaatttgctg gcggtggcca    780 
gacctagggg aagggcgaag tccctagggg aggaagatgg gtgcgagagc gtctgtgttg    840 
acagggagta aattggatgc atgggaacga attaggttaa ggccaggatc taaaaaggca    900 
tataggctaa aacatttagt atgggcaagc agggagctgg aaagatacgc atgtaatcct    960 
ggtctattag aaactgcaga aggtactgag caactgctac agcagttaga gccagctctc   1020 
aagacagggt cagaggacct gaaatctctc tggaacgcaa tagcagtact ctggtgcgtt   1080 
cacaacagat ttgacatccg agatacacag caggcaatac aaaagttaaa ggaagtaatg   1140 
gcaagcagga agtctgcaga ggccgctaag gaagaaacaa gccctaggca gacaagtcaa   1200 
aattacccta tagtaacaaa tgcacaggga caaatggtac atcaagccat ctcccccagg   1260 
actttaaatg catgggtaaa ggcagtagaa gagaaggcct ttaaccctga aattattcct   1320 
atgtttatgg cattatcaga aggggctgtc ccctatgata tcaataccat gctgaatgcc   1380 
atagggggac accaaggggc tttacaagtg ttgaaggaag taatcaatga ggaagcagca   1440 
gaatgggata gaactcatcc accagcaatg gggccgttac caccagggca gataagggaa   1500 
ccaacaggaa gtgacattgc tggaacaact agcacacagc aagagcaaat tatatggact   1560 
actagagggg ctaactctat cccagtagga gacatctata gaaaatggat agtgctagga   1620 
ctaaacaaaa tggtaaaaat gtacagtcca gtgagcatct tagatattag gcagggacca   1680 
aaagaaccat tcagagatta tgtagatcgg ttttacaaaa cattaagagc tgagcaagct   1740 
actcaagaag taaagaattg gatgacagaa accttgcttg ttcagaattc aaacccagat   1800 
tgtaaacaaa ttctgaaagc attaggacca gaagctactt tagaagaaat gatggtagcc   1860 
tgtcaaggag taggagggcc aactcacaag gcaaaaatac tagcagaagc aatggcttct   1920 
gcccagcaag atttaaaagg aggatacaca gcagtattca tgcaaagagg gcagaatcca   1980 
aatagaaaag ggcccataaa atgcttcaat tgtggaaaag agggacatat agcaaaaaac   2040 
tgtcgagcac ctagaaaaag gggttgctgg aaatgtggac aggaaggtca ccaaatgaaa   2100 
gattgcaaaa atggaagaca ggcaaatttt ttagggaagt actggcctcc ggggggcacg   2160 
aggccaggca attatgtgca gaaacaagtg tccccatcag ccccaccaat ggaggaggca   2220 
gtgaaggaac aagagaatca gagtcagaag ggggatcagg aagagctgta cccatttgcc   2280 
tccctcaaat ccctctttgg gacagaccaa tagtcacagc aaaggttggg ggtcatctat   2340 
gtgaggcttt actggataca ggggcagatg atacagtatt aaataacata caattagaag   2400 
gaagatggac accaaaaatg atagggggta taggaggctt tataaaagta aaagagtata   2460 
acaatgtgac agtagaagta caaggaaagg aagtacaggg aacagtattg gtgggaccta   2520 
ctcctgttaa tattcttggg agaaacatat tgacaggatt aggatgtaca ctaaatttcc   2580 
ctataagtcc catagcccca gtgccagtaa agctaaaacc aggaatggat ggaccaaaag   2640 
taaaacaatg gcccctatct agagagaaaa tagaagcact aactgcaata tgtcaagaaa   2700 
tggaacagga aggaaaaatc tcaagaatag gacctgaaaa tccttataat acacctattt   2760 
ttgctataaa aaagaaagat agcactaagt ggagaaaatt ggtagacttc agagaattaa   2820 
ataaaagaac acaagatttc tgggaggtgc aattaggtat tccacatcca gggggtttaa   2880 
agcaaaggca atctgttaca gtcttagatg taggagatgc ttatttctca tgccctttag   2940 
atccagactt tagaaaatac actgccttca ctattcctag tgtgaacaat gagaccccag   3000 
gagtaagata ccagtacaat gtcctcccgc aagggtggaa aggttcacca gccatatttc   3060 
agagttcaat gacaaagatt ctagatccat ttagaaaaag caacccagaa gtagaaattt   3120 
atcagtacat agatgactta tatgtaggat cagatttacc attggcagaa catagaaaga   3180 
gggtcgaatt gcttagggaa catttatatc agtggggatt tactacccct gataaaaagc   3240 
atcagaagga acctcccttt ttatggatgg gatatgagct ccacccagac aagtggacag   3300 
tacagcccat ccaattgcct gacaaagaag tgtggacagt aaatgatata caaaaattag   3360 
taggaaaatt aaattgggca agtcaaatct atcaaggaat tagagtaaaa gaattgtgca   3420 
agttaatcag aggaaccaaa tcattgacag aggtagtacc tttaagtaaa gaggcagaac   3480 
tagaattaga agaaaacaga gaaaagctaa aagagccagt acatggagta tattaccagc   3540 
ctgacaaaga cttgtgggtt agtattcaga agcatggaga agggcaatgg acttaccagg   3600 
tatatcagga tgaacataag aaccttaaaa caggaaaata tgctaggcaa aaggcctccc   3660 
acacaaatga tataagacaa ttggcagaag tagtccagaa ggtgtctcaa gaagctatag   3720 
ttatatgggg gaaattacct aaattcaggc tgccagttac tagagaaact tgggaaactt   3780 
ggtgggcaga atattggcag gccacctgga ttcctgaatg ggaatttgtc agcacacccc   3840 
cattgatcaa attatggtac cagttagaaa cagaacctat tgtaggggca gaaacctttt   3900 
atgtagatgg agcagctaat aggaatacaa aactaggaaa ggcgggatat gttacagaac   3960 
aaggaaaaca gaacataata aagttagaag agacaaccaa tcaaaaggct gaattaatgg   4020 
ctgtattaat agccttgcag gattccaagg agcaagtaaa catagtaaca gactcacaat   4080 
atgtattggg catcatatcc tcccaaccaa cacagagtga ctcccctata gttcagcaga   4140 
taatagagga actaacaaaa aaggaacgag tgtatcttac atgggttcct gctcacaaag   4200 
gcataggagg aaatgaaaaa atagataaat tagtaagcaa agacattaga agagtcctgt   4260 
tcctggaagg aatagatcag gcacaagaag atcatgaaaa atatcatagt aattggagag   4320 
cattagctag tgactttgga ttaccaccaa tagtagccaa ggaaatcatt gctagttgtc   4380 
ctaaatgcca tataaaaggg gaagcaacgc atggtcaagt agactacagc ccagagatat   4440 
ggcaaatgga ttgtacacat ttagaaggca aaatcataat agttgctgtc catgtagcaa   4500 
gtgactttat agaagcagag gtgataccag cagaaacagg acaggaaact gcctatttcc   4560 
tgttaaaatt agcagcaaga tggcctgtca aagtaataca tacagacaat ggacctaatt   4620 
ttacaagtgc agccatgaaa gctgcatgtt ggtggacagg catacaacat gagtttggga   4680 
taccatataa tccacaaagt caaggagtag tagaagccat gaataaagaa ttaaaatcta   4740 
ttatacagca ggtgagggac caagcagagc atttaaaaac agcagtacaa atggcagtct   4800 
ttgttcacaa ttttaaaaga aaagggggga ttggggggta cactgcaggg gagagactaa   4860 
tagacatact agcatcacaa atacaaacaa cagaactaca aaaacaaatt ttaaaaatca   4920 
acaattttcg ggtctattac agagatagca gagaccctat ttggaaagga ccggcacaac   4980 
tcctgtggaa aggtgagggg gcagtagtca tacaagataa aggagacatt aaagtggtac   5040 
caagaagaaa ggcaaaaata atcagagatt atggaaaaca gatggcaggt actgatagta   5100 
tggcaaatag acagacagaa agtgaaagca tggaacagcc tggtgaaata ccataaatac   5160 
atgtctaaga aggccgcgaa ctggcgttat aggcatcatt atgaatccag gaatccaaaa   5220 
gtcagttcgg cggtgtatat tccagtagca gaagctgata tagtggtcac cacatattgg   5280 
ggattaatgc caggggaaag agaggaacac ttgggacatg gggttagtat agaatggcaa   5340 
tacaaggagt ataaaacaca gattgatcct gaaacagcag acaggatgat acatctgcat   5400 
tatttcacat gttttacaga atcagcaatc aggaaggcca ttctagggca gagagtgctg   5460 
accaagtgtg aatacctggc aggacatagt caggtaggga cactacaatt cttagccttg   5520 
aaagcagtag tgaaagtaaa aagaaataag cctcccctac ccagtgtcca gagattaaca   5580 
gaagatagat ggaacaagcc ctggaaaatc agggaccagc tagggagcca ttcaatgaat   5640 
ggacactaga gctcctggaa gagctgaaag aagaagcagt aagacatttc cctaggcctt   5700 
ggttacaagc ctgtgggcag tacatttatg agacttatgg agacacttgg gaaggagtta   5760 
tggcaattat aagaatctta caacaactac tgtttaccca ttatagaatt ggatgccaac   5820 
atagtagaat aggaattctc ccatctaaca caagaggaag aggaagaaga aatggatcca   5880 
gtagatcctg agatgccccc ttggcatcac cctgggagca agccccaaac cccttgtaat   5940 
aattgctatt gcaaaagatg ctgctatcat tgctatgttt gtttcacaaa gaagggtttg   6000 
ggaatctccc atggcaggaa gaagcgaaga agaccagcag ctgctgcaag ctatccagat   6060 
aataaagatc ctgtaccaga gcagtaagta acgctgatgc atcaagagaa cctgctagcc   6120 
ttaatagctt taagtgcttt gtgtcttata aatgtactta tatggttgtt taaccttaga   6180 
atttatttag tgcaaagaaa acaagataga agggagcagg aaatacttga aagattaagg   6240 
agaataaagg aaatcaggga tgacagtgac tatgaaagta atgaagaaga acaacaggaa   6300 
gtcatggagc ttatacatag ccatggcttt gctaatccca tgtttgagtt atagtaaaca   6360 
attgtatgcc acagtttatt ctggggtacc tgtatgggaa gaggcagcac cagtactatt   6420 
ctgtgcttca gatgctaacc taacaagcac tgaacagcat aatatttggg catcacaagc   6480 
ctgcgttcct acagatccca atccacatga atttccacta ggcaatgtga cagataactt   6540 
tgatatatgg aaaaattaca tggtggacca aatgcatgaa gacatcatta gtttgtggga   6600 
acagagttta aagccttgtg agaaaatgac tttcttatgt gtacaaatga actgtgtaga   6660 
tctgcaaaca aataaaacag gcctattaaa tgagacaata aatgagatga gaaattgtag   6720 
ttttaatgta actacagtcc tcacagacaa aaaggagcaa aaacaggctc tattctatgt   6780 
atcagatctg agtaaggtta atgactcaaa tgcagtaaat ggaacaacat atatgttaac   6840 
taattgtaac tccacaatta tcaagcaggc ctgtcccaag gtaagttttg agcccattcc   6900 
catacactat tgtgctccaa caggatatgc catctttaag tgtaatgaca cagactttaa   6960 
tggaacaggc ctatgccaca atatttcagt ggttacttgt acacatggca tcaagccaac   7020 
agtaagtact caactaatac tgaatgggac actctctaga gaaaagataa gaattatggg   7080 
aaaaaatatt acagaatcag caaagaatat catagtaacc ctaaacactc ctataaacat   7140 
gacctgcata agagaaggaa ttgcagaggt acaagatata tatacaggtc caatgagatg   7200 
gcgcagtatg acacttaaaa gaagtaacaa tacatcacca agatcaaggg tagcttattg   7260 
tacatataat aagactgtat gggaaaatgc cctacaacaa acagctataa ggtatttaaa   7320 
tcttgtaaac caaacagaga atgttaccat aatattcagc agaactagtg gtggagatgc   7380 
agaagtaagc catttacatt ttaactgtca tggagaattc ttttattgta acacatctgg   7440 
gatgtttaac tatactttta tcaactgtac aaagtccgga tgccaggaga tcaaagggag   7500 
caatgagacc aataaaaatg gtactatacc ttgcaagtta agacagctag taagatcatg   7560 
gatgaaggga gagtcgagaa tctatgcacc tcccatcccc ggcaacttaa catgtcattc   7620 
caacataact ggaatgattc tacagttaga tcaaccatgg aattccacag gtgaaaatac   7680 
acttagacca gtagggggag atatgaaaga tatatggaga actaaattgt acaactacaa   7740 
agtagtacag ataaaacctt ttagtgtagc acctacaaaa atgtcaagac caataataaa   7800 
cattcacacc cctcacaggg aaaaaagagc agtaggattg ggaatgctat tcttgggggt   7860 
gctaagtgca gcaggtagca ctatgggcgc agcggcaaca gcgctgacgg tacggaccca   7920 
cagtgtactg aagggtatag tgcaacagca ggacaacctg ctgagagcga tacaggccca   7980 
gcaacacttg ctgaggttat ctgtatgggg tattagacaa ctccgagctc gcctgcaagc   8040 
cttagaaacc cttatacaga atcagcaacg cctaaaccta tggggctgta aaggaaaact   8100 
aatctgttac acatcagtaa aatggaacac atcatggtca ggaagatata atgatgacag   8160 
tatttgggac aaccttacat ggcagcaatg ggaccaacac ataaacaatg taagctccat   8220 
tatatatgat gaaatacaag cagcacaaga ccaacaggaa aagaatgtaa aagcattgtt   8280 
ggagctagat gaatgggcct ctctttggaa ttggtttgac ataactaaat ggttgtggta   8340 
tataaaaata gctataatca tagtgggagc actaataggt ataagagtta ttatgataat   8400 
acttaatcta gtgaagaaca ttaggcaggg atatcaaccc ctctcgttgc agatccctgt   8460 
cccacaccgg caggaagcag aaacgccagg aagaacagga gaagaaggtg gagaaggaga   8520 
caggcccaag tggacagcct tgccaccagg attcttgcaa cagttgtaca cggatctcag   8580 
gacaataatc ttgtggactt accacctctt gagcaactta atatcaggga tccggaggct   8640 
gatcgactac ctgggactgg gactgtggat cctgggacaa aagacaattg aagcttgtag   8700 
actttgtgga gctgtaatgc aatattggct acaagaattg aaaaatagtg ctacaaacct   8760 
gcttgatact attgcagtgt cagttgccaa ttggactgac ggcatcatct taggtctaca   8820 
aagaatagga caaggattcc ttcacatccc aagaagaatt agacaaggtg cagaaagaat   8880 
cttagtgtaa catggggaat gcatggagca aaagcaaatt tgcaggatgg tcagaagtaa   8940 
gagatagaat gagacgatcc tcctctgatc ctcaacaacc atgtgcacct ggagtaggag   9000 
ctgtctccag ggagttagca actagagggg gaatatcaag ttcccacact cctcaaaaca   9060 
atgcagccct tgcattccta gacagccaca aagatgagga tgtaggcttc ccagtaagac   9120 
ctcaagtgcc tctaaggcca atgaccttta aagcagcctt tgacctcagc ttctttttaa   9180 
aagaaaaggg aggactggat gggttaattt actcccataa gagagcagaa atcctggatc   9240 
tctggatata tcacactcag ggattcttcc ctgattggca gtgttacaca ccgggaccag   9300 
gacctagatt cccactgaca tttggatggt tgtttaaact ggtaccagtg tcagcagaag   9360 
aggcagagag actgggtaat acaaatgaag atgctagtct tctacatcca gcttgtaatc   9420 
atggagctga ggatgcacac ggggagatac taaaatggca gtttgataga tcattaggct   9480 
taacacatat agccctgcaa aagcacccag agctcttccc caagtaactg acactgcggg   9540 
actttccaga ctgctgacac tgcggggact ttccagcgtg ggagggataa ggggcggttc   9600 
ggggagtggc taaccctcag atgctgcata taagcagctg ctttccgctt gtaccgggtc   9660 
ttagttagag gaccaggtct gagcccggga gctccctggc ctctagctga acccgctgct   9720 
taacgctcaa taaagcttgc cttgagtgag aagcagtgtg tgctcatctg ttcaaccctg   9780 
gtgtctagag atc                                                      9793 
</s400>
<s200>
<s210>57 </s210>
<s211>1733 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 57 
aaacctccga cgcaacgggc tcggcttagc ggagtgcacc tgctaagagg cgagaggaac     60 
tcacaagagg gtgagtaaat ttgctggcgg tggccagacc taggggaagg gcgaagtccc    120 
taggggagga agatgggtgc gagagcgtct gtgttgacag ggagtaaatt ggatgcatgg    180 
gaacgaatta ggttaaggcc aggatctaaa aaggcatata ggctaaaaca tttagtatgg    240 
gcaagcaggg agctggaaag atacgcatgt aatcctggtc tattagaaac tgcagaaggt    300 
actgagcaac tgctacagca gttagagcca gctctcaaga cagggtcaga ggacctgaaa    360 
tctctctgga acgcaatagc agtactctgg tgcgttcaca acagatttga catccgagat    420 
acacagcagg caatacaaaa gttaaaggaa gtaatggcaa gcaggaagtc tgcagaggcc    480 
gctaaggaag aaacaagccc taggcagaca agtcaaaatt accctatagt aacaaatgca    540 
cagggacaaa tggtacatca agccatctcc cccaggactt taaatgcatg ggtaaaggca    600 
gtagaagaga aggcctttaa ccctgaaatt attcctatgt ttatggcatt atcagaaggg    660 
gctgtcccct atgatatcaa taccatgctg aatgccatag ggggacacca aggggcttta    720 
caagtgttga aggaagtaat caatgaggaa gcagcagaat gggatagaac tcatccacca    780 
gcaatggggc cgttaccacc agggcagata agggaaccaa caggaagtga cattgctgga    840 
acaactagca cacagcaaga gcaaattata tggactacta gaggggctaa ctctatccca    900 
gtaggagaca tctatagaaa atggatagtg ctaggactaa acaaaatggt aaaaatgtac    960 
agtccagtga gcatcttaga tattaggcag ggaccaaaag aaccattcag agattatgta   1020 
gatcggtttt acaaaacatt aagagctgag caagctactc aagaagtaaa gaattggatg   1080 
acagaaacct tgcttgttca gaattcaaac ccagattgta aacaaattct gaaagcatta   1140 
ggaccagaag ctactttaga agaaatgatg gtagcctgtc aaggagtagg agggccaact   1200 
cacaaggcaa aaatactagc agaagcaatg gcttctgccc agcaagattt aaaaggagga   1260 
tacacagcag tattcatgca aagagggcag aatccaaata gaaaagggcc cataaaatgc   1320 
ttcaattgtg gaaaagaggg acatatagca aaaaactgtc gagcacctag aaaaaggggt   1380 
tgctggaaat gtggacagga aggtcaccaa atgaaagatt gcaaaaatgg aagacaggca   1440 
aattttttag ggaagtactg gcctccgggg ggcacgaggc caggcaatta tgtgcagaaa   1500 
caagtgtccc catcagcccc accaatggag gaggcagtga aggaacaaga gaatcagagt   1560 
cagaaggggg atcaggaaga gctgtaccca tttgcctccc tcaaatccct ctttgggaca   1620 
gaccaatagt cacagcaaag gttgggggtc atctatgtga ggctttactg gatacagggg   1680 
cagatgatac agtattaaat aacatacaat tagaaggaag atggacacca aaa          1733 
</s400>
<s200>
<s210>58 </s210>
<s211>1733 </s211>
<s212>DNA </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 58 
aaacctccaa cgcaacgggc tcggcttagc ggagtgcacc tgctaagagg cgagaggaac     60 
tcacaagagg gtgagtaaat ttgctggcgg tggccagacc taggggaagg gcgaagtccc    120 
taggggagga agatgggtgc gagacggtct gtgttgacag ggagtaaatt ggatgcatgg    180 
gaacgaatta ggttaaggcc aggatctaaa aaggcatata ggctaaaaca tttagtatgg    240 
gcaagcaggg agctggaaag atacgcatat aatcctggtc tactagaaac tgcagaaggt    300 
actgaacaac tgctacagca gttagagcca gctctcaaga cagggtcaga ggacctgaaa    360 
tccctctgga acgcaatagc agtactctgg tgcgttcaca acagatttga catccgagat    420 
acacagcagg caatacaaaa gttaaaggaa gtaatggcaa gcaggaagtc tgcagaggcc    480 
gctaaggaag aaacaagctc aaggcaggca agtcaaaatt accctatagt aacaaatgca    540 
cagggacaaa tggtacatca agccatatcc cctaggactt taaatgcatg ggtaaaggca    600 
gtagaagaaa aggcctttaa ccctgaaatt attcctatgt ttatggcatt atcagaaggg    660 
gctgtcccct atgatatcaa taccatgctg aatgccatag ggggacacca aggggcttta    720 
caagtgttga aggaagtaat caatgaggaa gcagcagatt gggatagaac tcatccacca    780 
gcaatggggc cgttaccacc agggcagata agggaaccaa caggaagtga cattgctgga    840 
acaactagca cacagcaaga gcaaattata tggactacta gaggggctaa ctctatccca    900 
gtaggagaca tctatagaaa atggatagtg ttaggactaa acaaaatggt aaaaatgtac    960 
agtccagtga gcatcttaga tattaggcag ggaccaaaag aaccattcag agattatgta   1020 
gatcggtttt acaaaacatt aagagctgag caagctactc aagaagtaaa gaattggatg   1080 
acagaaaccc tcgttgttca gaattcaaac ccagattgta aacaaattct gaaagcatta   1140 
ggaccaggag ctactttaga agaaatgatg gtagcctgtc aaggagtagg agggccaact   1200 
cacaaggcaa aaatactagc agaagcaatg gcttctgccc agcaagattt aaagggagga   1260 
tacacagcag tattcatgca aagagggcag aatccaaata gaaaagggcc tataaaatgt   1320 
ttcaattgtg gaaaagaggg acatatagca aaaaactgtc gagcacctag aagaaggggt   1380 
tactggaaat gtggacagga aggtcaccaa atgaaagatt gcaaaaatgg aagacaggct   1440 
atttttttag ggaagtactg gcctccgggg ggcacgaggc cagccaatta tgtgcagaaa   1500 
caagtgtccc catcagcccc accaatggag gaggcagtga aggaacaaga gaatcagaat   1560 
caaaaggggg atcaggaaga gctgtaccca tttgcctccc tcaaatccct ctttgggaca   1620 
gaccaatagt cacagcaaag gttgggggcc atctatgtga ggctttactg gatacagggg   1680 
cagatgatac agtattaaat aacatacaat tagaaggaag atggacaccc aaa          1733 
</s400>
<s200>
<s210>59 </s210>
<s211>498 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 59 
Met Gly Ala Arg Ala Ser Val Leu Thr Gly Ser Lys Leu Asp Ala Trp 
  1               5                  10                  15 
Glu Arg Ile Arg Leu Arg Pro Gly Ser Lys Lys Ala Tyr Arg Leu Lys 
             20                  25                  30 
His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Tyr Ala Cys Asn Pro 
         35                  40                  45 
Gly Leu Leu Glu Thr Ala Glu Gly Thr Glu Gln Leu Leu Gln Gln Leu 
     50                  55                  60 
Glu Pro Ala Leu Lys Thr Gly Ser Glu Asp Leu Lys Ser Leu Trp Asn 
 65                  70                  75                  80 
Ala Ile Ala Val Leu Trp Cys Val His Asn Arg Phe Asp Ile Arg Asp 
                 85                  90                  95 
Thr Gln Gln Ala Ile Gln Lys Leu Lys Glu Val Met Ala Ser Arg Lys 
            100                 105                 110 
Ser Ala Glu Ala Ala Lys Glu Glu Thr Ser Pro Arg Gln Thr Ser Gln 
        115                 120                 125 
Asn Tyr Pro Ile Val Thr Asn Ala Gln Gly Gln Met Val His Gln Ala 
    130                 135                 140 
Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Ala Val Glu Glu Lys 
145                 150                 155                 160 
Ala Phe Asn Pro Glu Ile Ile Pro Met Phe Met Ala Leu Ser Glu Gly 
                165                 170                 175 
Ala Val Pro Tyr Asp Ile Asn Thr Met Leu Asn Ala Ile Gly Gly His 
            180                 185                 190 
Gln Gly Ala Leu Gln Val Leu Lys Glu Val Ile Asn Glu Glu Ala Ala 
        195                 200                 205 
Glu Trp Asp Arg Thr His Pro Pro Ala Met Gly Pro Leu Pro Pro Gly 
    210                 215                 220 
Gln Ile Arg Glu Pro Thr Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr 
225                 230                 235                 240 
Gln Gln Glu Gln Ile Ile Trp Thr Thr Arg Gly Ala Asn Ser Ile Pro 
                245                 250                 255 
Val Gly Asp Ile Tyr Arg Lys Trp Ile Val Leu Gly Leu Asn Lys Met 
            260                 265                 270 
Val Lys Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro 
        275                 280                 285 
Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg 
    290                 295                 300 
Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu 
305                 310                 315                 320 
Leu Val Gln Asn Ser Asn Pro Asp Cys Lys Gln Ile Leu Lys Ala Leu 
                325                 330                 335 
Gly Pro Glu Ala Thr Leu Glu Glu Met Met Val Ala Cys Gln Gly Val 
            340                 345                 350 
Gly Gly Pro Thr His Lys Ala Lys Ile Leu Ala Glu Ala Met Ala Ser 
        355                 360                 365 
Ala Gln Gln Asp Leu Lys Gly Gly Tyr Thr Ala Val Phe Met Gln Arg 
    370                 375                 380 
Gly Gln Asn Pro Asn Arg Lys Gly Pro Ile Lys Cys Phe Asn Cys Gly 
385                 390                 395                 400 
Lys Glu Gly His Ile Ala Lys Asn Cys Arg Ala Pro Arg Lys Arg Gly 
                405                 410                 415 
Cys Trp Lys Cys Gly Gln Glu Gly His Gln Met Lys Asp Cys Lys Asn 
            420                 425                 430 
Gly Arg Gln Ala Asn Phe Leu Gly Lys Tyr Trp Pro Pro Gly Gly Thr 
        435                 440                 445 
Arg Pro Gly Asn Tyr Val Gln Lys Gln Val Ser Pro Ser Ala Pro Pro 
    450                 455                 460 
Met Glu Glu Ala Val Lys Glu Gln Glu Asn Gln Ser Gln Lys Gly Asp 
465                 470                 475                 480 
Gln Glu Glu Leu Tyr Pro Phe Ala Ser Leu Lys Ser Leu Phe Gly Thr 
                485                 490                 495 
Asp Gln 
</s400>
<s200>
<s210>60 </s210>
<s211>498 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 60 
Met Gly Ala Arg Arg Ser Val Leu Thr Gly Ser Lys Leu Asp Ala Trp 
  1               5                  10                  15 
Glu Arg Ile Arg Leu Arg Pro Gly Ser Lys Lys Ala Tyr Arg Leu Lys 
             20                  25                  30 
His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Tyr Ala Tyr Asn Pro 
         35                  40                  45 
Gly Leu Leu Glu Thr Ala Glu Gly Thr Glu Gln Leu Leu Gln Gln Leu 
     50                  55                  60 
Glu Pro Ala Leu Lys Thr Gly Ser Glu Asp Leu Lys Ser Leu Trp Asn 
 65                  70                  75                  80 
Ala Ile Ala Val Leu Trp Cys Val His Asn Arg Phe Asp Ile Arg Asp 
                 85                  90                  95 
Thr Gln Gln Ala Ile Gln Lys Leu Lys Glu Val Met Ala Ser Arg Lys 
            100                 105                 110 
Ser Ala Glu Ala Ala Lys Glu Glu Thr Ser Ser Thr Gln Ala Ser Gln 
        115                 120                 125 
Asn Tyr Pro Ile Val Thr Asn Ala Gln Gly Gln Met Val His Gln Ala 
    130                 135                 140 
Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Ala Val Glu Glu Lys 
145                 150                 155                 160 
Ala Phe Asn Pro Glu Ile Ile Pro Met Phe Met Ala Leu Ser Glu Gly 
                165                 170                 175 
Ala Val Pro Tyr Asp Ile Asn Thr Met Leu Asn Ala Ile Gly Gly His 
            180                 185                 190 
Gln Gly Ala Leu Gln Val Leu Lys Glu Val Ile Asn Glu Glu Ala Ala 
        195                 200                 205 
Asp Trp Asp Arg Thr His Pro Pro Ala Met Gly Pro Leu Pro Pro Gly 
    210                 215                 220 
Gln Ile Arg Glu Pro Thr Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr 
225                 230                 235                 240 
Gln Gln Glu Gln Ile Ile Trp Thr Thr Arg Gly Ala Asn Ser Ile Pro 
                245                 250                 255 
Val Gly Asp Ile Tyr Arg Lys Trp Ile Val Leu Gly Leu Asn Lys Met 
            260                 265                 270 
Val Lys Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro 
        275                 280                 285 
Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg 
    290                 295                 300 
Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu 
305                 310                 315                 320 
Val Val Gln Asn Ser Asn Pro Asp Cys Lys Gln Ile Leu Lys Ala Leu 
                325                 330                 335 
Gly Pro Gly Ala Thr Leu Glu Glu Met Met Val Ala Cys Gln Gly Val 
            340                 345                 350 
Gly Gly Pro Thr His Lys Ala Lys Ile Leu Ala Glu Ala Met Ala Ser 
        355                 360                 365 
Ala Gln Gln Asp Leu Lys Gly Gly Tyr Thr Ala Val Phe Met Gln Arg 
    370                 375                 380 
Gly Gln Asn Pro Asn Arg Lys Gly Pro Ile Lys Cys Phe Asn Cys Gly 
385                 390                 395                 400 
Lys Glu Gly His Ile Ala Lys Asn Cys Arg Ala Pro Arg Arg Arg Gly 
                405                 410                 415 
Tyr Trp Lys Cys Gly Gln Glu Gly His Gln Met Lys Asp Cys Lys Asn 
            420                 425                 430 
Gly Arg Gln Ala Asn Phe Leu Gly Lys Tyr Trp Pro Pro Gly Gly Thr 
        435                 440                 445 
Arg Pro Ala Asn Tyr Val Gln Lys Gln Val Ser Pro Ser Ala Pro Pro 
    450                 455                 460 
Met Glu Glu Ala Val Lys Glu Gln Glu Asn Gln Asn Gln Lys Gly Asp 
465                 470                 475                 480 
Gln Glu Glu Leu Tyr Pro Phe Ala Ser Leu Lys Ser Leu Phe Gly Thr 
                485                 490                 495 
Asp Gln 
</s400>
<s200>
<s210>61 </s210>
<s211>35 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus type 1 </s213>
</s200>
<s400> 61 
Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly 
  1               5                  10                  15 
Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val Pro Trp 
             20                  25                  30 
Asn Ala Ser 
         35 
</s400>
<s200>
<s210>62 </s210>
<s211>35 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 62 
Arg Leu Gln Ala Leu Glu Thr Leu Ile Gln Asn Gln Gln Arg Leu Asn 
  1               5                  10                  15 
Leu Trp Gly Cys Lys Gly Lys Leu Ile Cys Tyr Thr Ser Val Lys Trp 
             20                  25                  30 
Asn Thr Ser 
         35 
</s400>
<s200>
<s210>63 </s210>
<s211>25 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus </s213>
</s200>
<s400> 63 
Trp Gly Ile Arg Gln Leu Arg Ala Arg Leu Gln Ala Leu Glu Thr Leu 
  1               5                  10                  15 
Ile Gln Asn Gln Gln Arg Leu Asn Leu 
             20                  25 
</s400>
<s200>
<s210>64 </s210>
<s211>22 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 64 
ccataatatt cagcagaact ag                                              22 
</s400>
<s200>
<s210>65 </s210>
<s211>18 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Description of Artificial Sequence primer </s223>
</s220>
</s200>
<s400> 65 
gctgattctg tataaggg                                                   18 
</s400>
<s200>
<s210>66 </s210>
<s211>36 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus type 1 </s213>
</s200>
<s400> 66 
Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gln Arg 
  1               5                  10                  15 
Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys Ile Gly Asn Met Arg 
             20                  25                  30 
Gln Ala His Cys 
         35 
</s400>
<s200>
<s210>67 </s210>
<s211>36 </s211>
<s212>PRT </s212>
<s213>Human immunodeficiency virus type 2 </s213>
</s200>
<s400> 67 
Cys Lys Arg Pro Gly Asn Lys Ile Val Lys Gln Ile Met Leu Met Ser 
  1               5                  10                  15 
Gly His Val Phe His Ser His Tyr Gln Pro Ile Asn Lys Arg Pro Arg 
             20                  25                  30 
Gln Ala Trp Cys 
         35
</s400>
</sequence-list-new-rules>
</sequence-cwu>
<subdoc-claims>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>) An immunodeficiency virus of the HIV group, or variants of this virus, which exhibits the essential morphological and immunological properties of the retrovirus which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 92 318. </claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>) The immunodeficiency virus as claimed in <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, which exhibits a protein band in a Western blot which corresponds to reverse transcriptase and is 3-7 kilodaltons smaller than the corresponding band of the HIV-1 and/or HIV-2 viruses. </claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>) The immunodeficiency virus as claimed in one of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> or <highlight><bold>2</bold></highlight>, which retrovirus exhibits less reactivity with a monoclonal antibody directed against protein p 24, related to reverse transcriptase activity, than does the HIV-1 virus, and more activity, related to the activity of reverse transcriptase, than does HIV-2. </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>) The immunodeficiency virus as claimed in one of the preceding claims, wherein antigen/antibody reactions with its transmembrane protein gp 41 are readily detectable using sera from patients originating from Africa, and wherein only a relatively small antigen/antibody reaction, or no such reaction, can be detected with the gp-41 using sera from patients originating from Germany. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>) The immunodeficiency virus as claimed in one of the abovementioned claims, which has an RNA sequence which is homologous to the extent of about 75% or more, based on the entire genome, with the RNA of the deposited virus. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>) The immunodeficiency virus as claimed in one of the abovementioned claims, which has an RNA sequence which is homologous to the extent of at least 75% with the RNA sequence of Table 1. </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>) The immunodeficiency virus as claimed in one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00005">5</dependent-claim-reference>, which has a nucleotide sequence which is homologous to the extent of at least 75% with the sequence of Table 3, or parts thereof. </claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>) The immunodeficiency virus as claimed in <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference>, wherein the part of the sequence is at least 50 nucleotides long. </claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>) The immunodeficiency virus as claimed in one of the preceding claims, which has a sequence or constituent sequence which corresponds to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> or is homologous to this sequence, where the differences from the sequence given in <cross-reference target="DRAWINGS">FIG. 4</cross-reference>, related to the gene loci, are at most: LTR: 17%, GAG: 29%, POL: 25%, VIF: 31%, ENV: 46%, NEF: 16%. </claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>) The immunodeficiency virus as claimed in one of the preceding claims, which has a sequence or constituent sequence which corresponds to <cross-reference target="DRAWINGS">FIG. 4</cross-reference> or is homologous to this sequence, where the differences from the sequence given in <cross-reference target="DRAWINGS">FIG. 4</cross-reference>, related to the gene loci, are at most: LTR: 10%, GAG: 14%, POL: 12%, VIF: 15%, ENV: 22%, NEF: 10%. </claim-text>
</claim>
<claim id="CLM-00011">
<claim-text><highlight><bold>11</bold></highlight>) cDNA which is complementary to the RNA, or parts thereof, of the immunodeficiency virus MVP-5180/91 deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 92 318, or of a virus as claimed in one of claims <highlight><bold>1</bold></highlight>-<highlight><bold>10</bold></highlight>. </claim-text>
</claim>
<claim id="CLM-00012">
<claim-text><highlight><bold>12</bold></highlight>) Recombinant DNA which contains cDNA as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 11</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00013">
<claim-text><highlight><bold>13</bold></highlight>) An antigen which was prepared using the cDNA as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 11</dependent-claim-reference> or the recombinant DNA as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 12</dependent-claim-reference>, or using the amino acid structure which can be deduced from its cDNA. </claim-text>
</claim>
<claim id="CLM-00014">
<claim-text><highlight><bold>14</bold></highlight>) The antigen as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 13</dependent-claim-reference>, which is a protein or peptide. </claim-text>
</claim>
<claim id="CLM-00015">
<claim-text><highlight><bold>15</bold></highlight>) The antigen as claimed in one of <dependent-claim-reference depends_on="CLM-00011">claim 13</dependent-claim-reference> or <highlight><bold>14</bold></highlight>, which has an amino acid sequence which corresponds to Table 3 or to a constituent sequence thereof. </claim-text>
</claim>
<claim id="CLM-00016">
<claim-text><highlight><bold>16</bold></highlight>) The antigen as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 15</dependent-claim-reference>, wherein the constituent sequence has at least 10 amino acids. </claim-text>
</claim>
<claim id="CLM-00017">
<claim-text><highlight><bold>17</bold></highlight>) The antigen as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 15</dependent-claim-reference>, which has the amino acid sequence RLQALETLIQNQQRLNLWGCKGKLICYTSVKWNTS, or a constituent sequence thereof having at least 6 consecutive amino acids. </claim-text>
</claim>
<claim id="CLM-00018">
<claim-text><highlight><bold>18</bold></highlight>) An antigen which was prepared from an immunodeficiency virus as claimed in one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00010">10</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00019">
<claim-text><highlight><bold>19</bold></highlight>) The antigen as claimed in one of <dependent-claim-reference depends_on="CLM-00013">claims 13</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00018">18</dependent-claim-reference>, which was prepared recombinantly. </claim-text>
</claim>
<claim id="CLM-00020">
<claim-text><highlight><bold>20</bold></highlight>) The antigen as claimed in one of <dependent-claim-reference depends_on="CLM-00013">claims 13</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00017">17</dependent-claim-reference>, which was prepared synthetically. </claim-text>
</claim>
<claim id="CLM-00021">
<claim-text><highlight><bold>21</bold></highlight>) A test kit for detecting antibodies against viruses which cause immuno deficiency, wherein antigen as claimed in <dependent-claim-reference depends_on="CLM-00013">claims 13</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00020">20</dependent-claim-reference> is employed. </claim-text>
</claim>
<claim id="CLM-00022">
<claim-text><highlight><bold>22</bold></highlight>) The test kit as claimed in <dependent-claim-reference depends_on="CLM-00022">claim 21</dependent-claim-reference>, which is a Western blot. </claim-text>
</claim>
<claim id="CLM-00023">
<claim-text><highlight><bold>23</bold></highlight>) The test kit as claimed in <dependent-claim-reference depends_on="CLM-00022">claim 21</dependent-claim-reference>, which is an ELISA test or a fluorescence-antibody detection test. </claim-text>
</claim>
<claim id="CLM-00024">
<claim-text><highlight><bold>24</bold></highlight>) Use of the immunodeficiency virus as claimed in one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00010">10</dependent-claim-reference> and/or of the cDNA as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 11</dependent-claim-reference> or <highlight><bold>12</bold></highlight> and/or of an antigen as claimed in <dependent-claim-reference depends_on="CLM-00013">claims 13</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00020">20</dependent-claim-reference> for detecting retroviruses which cause immune deficiency. </claim-text>
</claim>
<claim id="CLM-00025">
<claim-text><highlight><bold>25</bold></highlight>) Use of a retrovirus as claimed in one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00010">10</dependent-claim-reference>, of a cDNA as claimed in <dependent-claim-reference depends_on="CLM-00011">claim 11</dependent-claim-reference> or <highlight><bold>12</bold></highlight> and/or of an antigen as claimed in <dependent-claim-reference depends_on="CLM-00013">claims 13</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00020">20</dependent-claim-reference> for preparing vaccines. </claim-text>
</claim>
<claim id="CLM-00026">
<claim-text><highlight><bold>26</bold></highlight>) Ribonucleic acid characterized in that the ribonucleic acid is coding for an immunodeficiency virus according to one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00010">10</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00027">
<claim-text><highlight><bold>27</bold></highlight>. Virus MvP-5180/91, deposited with the European Collection of Animal Cell Culture (ECACC) under No. V 920 92 318. </claim-text>
</claim>
<claim id="CLM-00028">
<claim-text><highlight><bold>28</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that has a nucleotide sequence that shows at least 66% homology to SEQ ID NO:37 or SEQ ID NO:38. </claim-text>
</claim>
<claim id="CLM-00029">
<claim-text><highlight><bold>29</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00022">claim 28</dependent-claim-reference>, wherein said variant has a genome that has a nucleotide sequence that shows at least 75% homology to SEQ ID NO:37 or SEQ ID NO:38. </claim-text>
</claim>
<claim id="CLM-00030">
<claim-text><highlight><bold>30</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00022">claim 28</dependent-claim-reference>, wherein said variant has a genome that has a nucleotide sequence that shows at least 85% homology to SEQ ID NO:37 or SEQ ID NO:38. </claim-text>
</claim>
<claim id="CLM-00031">
<claim-text><highlight><bold>31</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that has a nucleotide sequence that shows at least 66% homology to SEQ ID NO:44 or SEQ ID NO:45. </claim-text>
</claim>
<claim id="CLM-00032">
<claim-text><highlight><bold>32</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 31</dependent-claim-reference>, wherein said variant has a genome that has a nucleotide sequence that shows at least 75% homology to SEQ ID NO:44 or SEQ ID NO:45. </claim-text>
</claim>
<claim id="CLM-00033">
<claim-text><highlight><bold>33</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 31</dependent-claim-reference>, wherein said variant has a genome that has a nucleotide sequence that shows at least 85% homology to SEQ ID NO:44 or SEQ ID NO:45. </claim-text>
</claim>
<claim id="CLM-00034">
<claim-text><highlight><bold>34</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 31</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 66% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 50 nucleotides. </claim-text>
</claim>
<claim id="CLM-00035">
<claim-text><highlight><bold>35</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 34</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 66% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 100 nucleotides. </claim-text>
</claim>
<claim id="CLM-00036">
<claim-text><highlight><bold>36</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 31</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 75% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 50 nucleotides. </claim-text>
</claim>
<claim id="CLM-00037">
<claim-text><highlight><bold>37</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 36</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 75% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 100 nucleotides. </claim-text>
</claim>
<claim id="CLM-00038">
<claim-text><highlight><bold>38</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 31</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 85% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 50 nucleotides. </claim-text>
</claim>
<claim id="CLM-00039">
<claim-text><highlight><bold>39</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00033">claim 38</dependent-claim-reference>, wherein said variant has a genome that has a sequence that shows at least 85% homology to SEQ ID NO:44 or SEQ ID NO:45 over at least 100 nucleotides. </claim-text>
</claim>
<claim id="CLM-00040">
<claim-text><highlight><bold>40</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 66% homology to SEQ ID NO:39. </claim-text>
</claim>
<claim id="CLM-00041">
<claim-text><highlight><bold>41</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 40</dependent-claim-reference>, wherein said variant has a genome that has a sequence that encodes a polypeptide that shows at least 75% homology to SEQ ID NO:39. </claim-text>
</claim>
<claim id="CLM-00042">
<claim-text><highlight><bold>42</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 40</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 85% homology to SEQ ID NQ:39. </claim-text>
</claim>
<claim id="CLM-00043">
<claim-text><highlight><bold>43</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 66% homology to SEQ ID NO:46. </claim-text>
</claim>
<claim id="CLM-00044">
<claim-text><highlight><bold>44</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 43</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 66% homology to SEQ ID NO:46 over at least 16 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00045">
<claim-text><highlight><bold>45</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 44</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 66% homology to SEQ ID NO:46 over at least 33 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00046">
<claim-text><highlight><bold>46</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 75% homology to SEQ ID NO:46. </claim-text>
</claim>
<claim id="CLM-00047">
<claim-text><highlight><bold>47</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 46</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 75% homology to SEQ ID NO:46 over at least 16 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00048">
<claim-text><highlight><bold>48</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 47</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 75% homology to SEQ ID NO:46 over at least 33 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00049">
<claim-text><highlight><bold>49</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 85% homology to SEQ ID NO:46. </claim-text>
</claim>
<claim id="CLM-00050">
<claim-text><highlight><bold>50</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00044">claim 49</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 85% homology to SEQ ID NO:46 over at least 16 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00051">
<claim-text><highlight><bold>51</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00055">claim 50</dependent-claim-reference>, wherein said variant has a genome that encodes a polypeptide that shows at least 85% homology to SEQ ID NO:46 over at least 33 amino acid residues. </claim-text>
</claim>
<claim id="CLM-00052">
<claim-text><highlight><bold>52</bold></highlight>. The virus of <dependent-claim-reference depends_on="CLM-00022">claim 28</dependent-claim-reference>, wherein said virus has a reverse transcriptase that is magnesium dependent, but not manganese dependent. </claim-text>
</claim>
<claim id="CLM-00053">
<claim-text><highlight><bold>53</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that has a nucleotide sequence that shows at least 98% homology to SEQ ID NO:57. </claim-text>
</claim>
<claim id="CLM-00054">
<claim-text><highlight><bold>54</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 97.8% homology to SEQ ID NO:59. </claim-text>
</claim>
<claim id="CLM-00055">
<claim-text><highlight><bold>55</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a genome that encodes a polypeptide that shows at least 77.8% homology to SEQ ID NO:54. </claim-text>
</claim>
<claim id="CLM-00056">
<claim-text><highlight><bold>56</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has an LTR that shows at least 83% homology to the long terminal repeat (LTR) of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00057">
<claim-text><highlight><bold>57</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00055">claim 56</dependent-claim-reference>, wherein said variant LTR shows at least 85% homology to the LTR of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00058">
<claim-text><highlight><bold>58</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00055">claim 56</dependent-claim-reference>, wherein said variant LTR shows at least 90% homology to the LTR of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00059">
<claim-text><highlight><bold>59</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a GAG gene that shows at least 71% homology to the GAG gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00060">
<claim-text><highlight><bold>60</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00055">claim 59</dependent-claim-reference>, wherein said variant LTR shows at least 72% homology to the GAG gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00061">
<claim-text><highlight><bold>61</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00055">claim 59</dependent-claim-reference>, wherein said variant LTR shows at least 86% homology to the LTR of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00062">
<claim-text><highlight><bold>62</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a POL gene that shows at least 75% homology to the POL gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00063">
<claim-text><highlight><bold>63</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 62</dependent-claim-reference>, wherein said variant POL gene shows at least 86% homology to the POL gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00064">
<claim-text><highlight><bold>64</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 62</dependent-claim-reference>, wherein said variant POL gene shows at least 88% homology to the POL gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00065">
<claim-text><highlight><bold>65</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has a VIF gene that shows at least 68% homology to the VIF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00066">
<claim-text><highlight><bold>66</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 65</dependent-claim-reference>, wherein said variant VIF gene shows at least 70% homology to the VIF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00067">
<claim-text><highlight><bold>67</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 65</dependent-claim-reference>, wherein said variant VIF gene shows at least 85% homology to the VIF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00068">
<claim-text><highlight><bold>68</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has an ENV gene that shows at least 54% homology to the ENV gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00069">
<claim-text><highlight><bold>69</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 68</dependent-claim-reference>, wherein said variant ENV gene shows at least 55% homology to the ENV gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00070">
<claim-text><highlight><bold>70</bold></highlight>. The variant virus of <dependent-claim-reference depends_on="CLM-00066">claim 68</dependent-claim-reference>, wherein said variant ENV gene shows at least 88% homology to the ENV gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00071">
<claim-text><highlight><bold>71</bold></highlight>. A variant virus, which is a variant of virus MvP-5180/91, wherein said variant has an NEF gene that shows at least 55% homology to the NEF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00072">
<claim-text><highlight><bold>72</bold></highlight>. The variant virus of claim <highlight><bold>71</bold></highlight>, wherein said variant NEF gene shows at least 84% homology to the NEF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00073">
<claim-text><highlight><bold>73</bold></highlight>. The variant virus of claim <highlight><bold>71</bold></highlight>, wherein said variant NEF gene shows at least 88% homology to the NEF gene of virus MvP-5180/91. </claim-text>
</claim>
<claim id="CLM-00074">
<claim-text><highlight><bold>74</bold></highlight>. The variant virus of claim <highlight><bold>71</bold></highlight>, wherein said variant NEF gene shows at least 90% homology to the NEF gene of virus MvP-5180/91.</claim-text>
</claim>
</subdoc-claims>
<subdoc-drawings id="DRAWINGS">
<heading lvl="0" align="CENTER">Drawings</heading>
<representative-figure>NONE</representative-figure>
<figure id="figure-D00001">
<image id="EMI-D00001" file="US20030003442A1-20030102-D00001.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00002">
<image id="EMI-D00002" file="US20030003442A1-20030102-D00002.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00003">
<image id="EMI-D00003" file="US20030003442A1-20030102-D00003.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00004">
<image id="EMI-D00004" file="US20030003442A1-20030102-D00004.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00005">
<image id="EMI-D00005" file="US20030003442A1-20030102-D00005.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00006">
<image id="EMI-D00006" file="US20030003442A1-20030102-D00006.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00007">
<image id="EMI-D00007" file="US20030003442A1-20030102-D00007.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00008">
<image id="EMI-D00008" file="US20030003442A1-20030102-D00008.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00009">
<image id="EMI-D00009" file="US20030003442A1-20030102-D00009.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00010">
<image id="EMI-D00010" file="US20030003442A1-20030102-D00010.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00011">
<image id="EMI-D00011" file="US20030003442A1-20030102-D00011.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00012">
<image id="EMI-D00012" file="US20030003442A1-20030102-D00012.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00013">
<image id="EMI-D00013" file="US20030003442A1-20030102-D00013.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00014">
<image id="EMI-D00014" file="US20030003442A1-20030102-D00014.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00015">
<image id="EMI-D00015" file="US20030003442A1-20030102-D00015.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00016">
<image id="EMI-D00016" file="US20030003442A1-20030102-D00016.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00017">
<image id="EMI-D00017" file="US20030003442A1-20030102-D00017.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00018">
<image id="EMI-D00018" file="US20030003442A1-20030102-D00018.TIF" imf="TIFF" ti="DR"/>
</figure>
</subdoc-drawings>
</patent-application-publication>
